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Abstract  
Acid-related disease (ARD) is a term used to describe a range of conditions in which 
acid is involved in the generation of symptoms and/or complications. Two of the most 
common ARDs are gastro-esophageal reflux disease (GERD) and peptic ulcer disease 
(PUD).  
PPIs are today regarded as the gold standard in the treatment of both symptoms and 
mucosal injury in patients with GERD as well as for prevention and acute treatment of 
PUD. Since the PPIs were introduced in the late 1980-ies there has been a sharp 
increase in the usage in the Western world. Although this increase coincides with the 
GERD epidemic it has also led to concerns related to PPI over-utilization, with high 
costs and associated long-term side-effects. In contrast, there is an apparent under-
utilization of PPIs as gastroprotective therapy in patients at elevated risk of PUD 
when taking certain medication. Observational studies have also suggested that the 
clinical efficacy of PPI therapy may be reduced because of poor adherence. Despite 
PPIs being among the most widely used prescription drugs there are scarce data on 
the natural utilization patterns of PPIs. Furthermore the implementation of various 
cost-containment programs, imposing restrictions on PPI prescriptions, has rarely 
been evaluated in a systematic manner. 
A much debated issue is whether the diagnosis and initial treatment of GERD, after 
excluding patients with an indication for prompt esophagogastroduodenoscopy (EGD) 
(alarm symptoms or age above 50 years), should be based on symptoms or if EGD 
shall be performed upfront. A number of patient reported questionnaires have been 
developed in order to facilitate the symptom-based diagnosis of GERD.  
In the first study a validation of a questionnaire (GerdQ) as a diagnostic tool for 
GERD was performed. A GerdQ cutoff score ≥9 gave the best balance between 
sensitivity, 66% (95% CI 58-74%) and specificity, 64% (95% CI 41-83%), for GERD. 
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It was concluded that GerdQ is a useful complementary tool for the diagnosis of 
GERD.  
In the second study the GerdQ questionnaire was integrated into an algorithm for the 
symptom-based diagnosis and initial treatment of patients with symptoms suggestive 
of GERD and compared against an endoscopy-based approach. In this randomized 
controlled trial patients with symptoms of GERD, but without alarm features, the 
symptom-based approach (response rate 87%) was non-inferior, but not superior 
(p=0.14) to the endoscopy-based approach (response rate 80%). The net cost-savings 
in the 8 weeks within-trial analysis was 146€ in favor of the symptom-based 
approach. To conclude we found that patients with a high likelihood of GERD (high 
GerdQ scores) profited from a symptom-based approach while patients with low 
likelihood of GERD (low GerdQ scores) favored further investigation with EGD/pH-
metry. 
In sum the first two papers show that when facilitated by GerdQ the responsibility for 
diagnosis and initial treatment of patients with GERD, without indication for EGD, 
could confidently be transferred to primary care. This will hopefully lead to a reduced 
number of costly and unnecessary referrals. 
In the third paper we used the Norwegian Prescription Database (NorPD) to retrieve 
all individual level prescriptions dispensed on a PPI from 1 January 2004 to 1 January 
2008. Dispensations (or the absence of dispensations) were used as a proxy for 
starting, shifting or discontinuing PPI therapy.  
The study found that although GERD is considered a chronic disease a considerable 
alteration in the pool of patients treated with PPI was demonstrated. High proportions 
of patients discontinued PPI therapy long-term (23% and 39% per year in two 
different periods) likely reflecting the relapsing-remitting nature of GERD or, but less 
likely, a lasting remission. The switch between different PPIs was low (5% and 7% in 
two different periods) likely reflecting the natural switching patterns due to treatment 
failure or intolerance. A new restrictive prescription policy program defining generic 
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alternatives as preferred treatment was successfully introduced among new PPI users 
with the proportion of patients receiving esomeprazole dropping from 57% before to 
20% after the introduction of the new policy. A mandatory shift in ongoing 
esomeprazole users was harder to implement with 64% not shifting from 
esomeprazole to generic PPI during the first year after implementation. Amongst the 
36% who shifted from esomeprazole to generic PPI, one out of four subsequently 
shifted back to esomeprazole. 
In the fourth paper we assessed the association between PPI adherence and the risk of 
upper GI complications (ulcer, bleeding and perforation) among NSAID users. This 
case-control study, being the largest of its kind, linked nationwide Swedish data from 
the Prescribed Drug Registry with the National Patient Registry. A total of 3.649 
cases of upper GI complications were identified. Patients with poor adherence (<20% 
PPI coverage) had approximately twice the risk of peptic ulcer (OR=1.88; 95% CI 
1.22-2.88) compared with fully adherent patients (≥80% PPI coverage). As NSAIDs 
are among the most frequently prescribed prescription drugs, and upper GI 
complications carry a high mortality risk, efforts to increase adherence with PPIs 
should be an integrated part of clinical practice.  
In sum this thesis addresses relevant questions of importance for the diagnosis and 
treatment of acid-related diseases. We have validated a questionnaire (GerdQ) as a 
diagnostic tool for GERD and also demonstrated that a symptom-based management 
algorithm is equally efficacious, but less costly, compared to an endoscopy based 
approach. The thesis has also provided intriguing new data on the natural utilization 
patterns for PPIs. Lastly it has been demonstrated that NSAID users with poor 
adherence to PPI have twice the risk of developing a serious upper GI event compared 
to full adherers. 
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1. Proton pump inhibitors (PPIs) in acid-related 
diseases 
1.1 Definition of acid-related diseases 
Acid-related diseases is a term used to describe a whole range of conditions from  
Zollinger-Ellison syndrome, where acid is almost entirely responsible for the problems 
to much more common conditions such as gastro-esophageal reflux disease (GERD) 
and peptic ulcer disease in which gastric acid and pepsin play a part in pathogenesis 
and symptom generation.  Within large groups of patients having GERD and 
functional dyspepsia there are also a spectrum of  subgroups of patients with varying 
degree of  influence by acid. This in turn leads to many different phenotypic 
presentations of disease which has direct implication for management.  
The term acid-related disease probably appeared as a result of the introduction of 
potent acid-suppressive drugs. In a way it is partly a misleading concept since acid is 
not directly involved in disease etiology. For instance, GERD is primarily a disease 
caused by impaired upper GI motility which in turn leads to acid juices being present 
at the wrong place. Acid-suppressive drugs merely prevent symptoms and 
complications by elevation of  pH, but do not have any impact on the 
pathophysiological causes of the disease. The same is true for peptic ulcer disease 
where the primary cause of disease is an impaired mucosal protection caused mainly 
by either intake of drugs (non-steroidal anti-inflammatory drugs  - NSAIDs) or gastric 
infection by Helicobacter pylori. In peptic ulcer disease acid aggravetes else sub-
clinical erosions to be developed into symptomatic ulcers, perforations and bleedings. 
This thesis will concentrate on two of the most common acid-related diseases, namely 
GERD and peptic ulcer disease.  
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1.2 Approved indications and reimbursement of PPIs  
PPIs are today regarded as the gold standard in the treatment of both symptoms and 
mucosal injury in patients with GERD as well as for the prevention and acute 
treatment of upper GI (UGI) complications caused by NSAID therapy. 
Reimbursement of first time use of PPIs for the treatment of GERD in Norway 
requires specialist consultation and the diagnosis of GERD needs to be verified by 
either EGD proven esophagitis or a pathological pH-metry. Reimbursement of PPI for 
NSAID associated peptic ulcer disease is more liberal in the sense that endoscopy is 
not necessary in order to initiate PPI therapy, but prescription must be restricted to 
patients with an elevated risk of UGI complications.  
1.3 Acid-suppressive medications 
The introduction of the histamine-2-receptor antagonists (H2RAs) during the 1970s 
represented a breakthrough in the management of patients with peptic ulcer disease 
and quickly changed therapy from surgery to medical treatment. In the treatment of 
GERD, however, the H2RA achieved only modest benefits in both clinical practice 
and controlled trials due to an insufficient effect on the pH of refluxed gastric juice 
and development of tolerance. Omeprazole was introduced in 1988 and the PPIs have 
since then been widely reported to induce more effective acid inhibition than H2RA, 
in particular the effect of PPIs on post-prandial reflux symptoms is clearly superior to 
H2RA. PPIs are now regarded the mainstay of medical treatment of acid-related 
diseases in GERD and peptic ulcer. 
1.4 Mechanism of action of PPIs 
Gastric acid secretion is a complex biological phenomenon involving both hormonal 
and neural stimulation. Neural stimulation occurs via the involvement of the vagal 
nerve which gets activated in response to smell, sight or taste of food. 
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The production of gastric acid in the stomach is tightly regulated by positive 
regulators and negative feedback mechanisms. Four types of cells are involved in this 
process: parietal cells, G cells, D cells and enterochromaffin-like (ECL) cells. Nerve 
endings in the stomach secrete the two stimulatory neurotransmitters acetylcholine 
(Ach) and gastrin. Their action is both direct on parietal cells and mediated through 
the secretion of gastrin from G cells and histamine from ECL cells. Gastrin acts on 
parietal cells directly and indirectly too, by stimulating the release of histamine. The 
release of histamine is the most important positive regulation mechanism of the 
secretion of gastric acid in the stomach.  
The activity of the proton pump (H+, K+-ATPase) in the parietal cell represents the 
final step of acid secretion. PPIs are targeted at blocking this enzyme which leads to 
an inhibition of acid secretion and an elevation of intragastric pH. All PPIs are weak 
bases and in contact with the acidic environment in the gastric glands they are 
protonated and accumulated in the secretory canaliculus, the highly acidic space in 
the parietal cell. Within the acidic space PPIs are transformed and binds covalently 
and almost irreversibly to the proton pump leading to a specific and sustained 
inhibition of acid secretion.  
PPIs are most effective when the parietal cell is stimulated to produce acid post-
prandially. Therefore the administration of PPIs is recommended 0.5-1.0 hour before 
a meal to make sure that PPI are absorbed and available in the blood. 
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Figure 1: Main stimulators (green) and inhibitors (red) involved in acid secretion 
leading to either activation or inhibition of the proton pump (H+, K+ ATPase) 
1.5 Efficacy and acid control with PPIs 
Despite all the available PPIs having different pharmacokinetics, pharmacodynamics 
and interaction potential, it is not always easy to see these minor differences 
transferring to a clinically meaningful difference between different PPIs. 
The number of hours or percent time of the day in which these agents raise 
intragastric pH over 4 is used as an indirect measure of acid control and is a 
recognized surrogate measure for clinical outcome. Omeprazole, pantoprazole and 
lansoprazole, in standard doses, are comparable in their control of intragastric pH over 
24 hours while a longer duration of intragastric pH control has been demonstrated 
with 40 mg esomeprazole.1  
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There is a correlation between acid secretion control, measured as percentage of time 
pH>4, with both reflux symptom resolution and healing of reflux esophagitis.2 3 
However, this correlation is of little relevance on an individual patient basis. 
About 80% of patients with reflux esophagitis are healed after 8 weeks on PPI therapy 
and roughly the same proportion of GERD patients are symptom-free. Symptom 
resolution rates are higher for patients with esophagitis compared to ENRD patients. 
1.6 Utilisation of PPI 
Ever since the introduction of H2RA in the early 70-ies and the PPIs in 1988 the costs 
of acid-suppressive drugs has been the major cost driver in the management of acid-
related disorders. However, this trend is now changing when PPIs lose their patents 
and cheaper generic copies are entering the market.  
There was a 2.1-fold increase in PPI utilization in Norway between 2001 and 2009 
rising from 16.9 DDD/TID (Defined Daily Doses / 1000 inhabitants per day) to 35.8.4 
In England, the prescribing of PPIs between 1998 and 2003 increased with 113% 
generating a total cost of £420 million to the National Health Service (NHS).5  
However, as a consequence of cost-containment reforms the cost of PPI, during the 
same periods, fell with 27% in Norway and 44% in England.4 5  
A self-generated report from the Norwegian Prescription Database (www.norpd.no) 
also confirms this trend with more patients being treated with PPI to a lesser cost. 
During the period from 2004 to 2011 the number of PPI users (defined as at least one 
PPI refill per year) increased with 72% while at the same time the turnover cost fell 
with 21% (see figure). 
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Figure 2: The pattern of PPI consumption (patients with at least one PPI refill/year) and PPI 
turnover by value (mill NOK) over the period 2004 to 2011. 
 
Governmental bodies and health insurance enterprises have introduced reforms to 
contain costs of PPI often by the introduction of therapeutic or generic substitution 
programs which necessitates use of generic PPIs before patented and more expensive 
PPIs. Some of these program demands a mandatory switch in patients already using 
PPIs. Since such a change is most often not clinically indicated it has proven difficult 
to accomplish. The net cost-saving is also debatable since a reduction in costs of drug 
can easily be outweighed by an increase in health care utilization, sick leave and 
productivity loss. 
The natural drug usage pattern of PPI treatment is poorly understood. Data from 
clinical trials where intake of PPI is controlled and patients tightly followed-up do not 
mimic ordinary utilization. In ordinary clinical practice patients often do not use drugs 
as prescribed and data from observational studies are needed in order to elucidate this 
aspect of drug treatment. This can have important implication in evaluating the 
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effectiveness, safety and health economical aspect of PPI treatment, but also help 
assessing adherence to PPI which is another important aspect of treatment success. 
1.6.1 Over-utilization of PPIs 
With the sharp increase in the usage of PPIs in the Western world the fear of over-
utilisation of PPI is increasing and has implications both in relation to health care 
expenditure and PPI related adverse events. A retrospective cohort study in the US, 
conducted in a Veteran Administration hospital, evaluated the indications for PPI 
therapy and showed that 36% of patients had no documented indication for PPI 
therapy.6 van Vliet et al. demonstrated that 40% of patients admitted to a pulmonary 
medicine wards used proton pump inhibitors (PPIs) without a registered indication.7  
While overutilization is a problem in clinical practise there are also patients with high 
symptom load who do not seek healthcare or use sub-optimal self-treatment. 
Consequently, there is at the same time a situation of both over- and under-treatment 
with PPIs. An example of under-utilization of PPIs is when used as gastroprotective 
therapy in patients at risk of upper GI bleedings and perforation. Several studies have 
shown that less than 40% of patients at elevated GI risk receive concurrent PPI 
gastroprotection.8-11 
1.6.2 Side-effect profile of PPIs 
PPIs are now among the most widely prescribed drugs in the world. Although these 
drugs are generally safe a number of potential side effects have been described. The 
most frequently reported short-term adverse effects of PPI are headache, nausea, 
diarrhoea and abdominal pain. In recent years retrospective observational studies have 
indicated an association between PPI use and osteoporosis-associated bone fractures, 
hypomagnesemia, Clostridium difficile infections and community-acquired 
pneumonia.12-15 Observational studies are subject to confounding and bias and hence 
the medical evidence for a causal relationship is still weak. While the relative risk is 
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quite strong for some of these associations the absolute risk of a complication is still 
low.  
It is evident that patients treated with a PPI develop secondary hypergastrinemia and 
subsequently ECL cell hyperplasia. The widespread and chronic use of PPIs has 
raised concerns over the potential risk of the development of ECL carcinoids when 
exposed to life-long and potent acid inhibition. During the early development phase of 
the PPIs it was shown that female rats developed gastric carcinoids when exposed to 
life-long PPI therapy, however, in retrospect this was found to be a species specific 
effect related to a 10 times higher gastrin production in rats compared to humans. 
There have been case reports arguing for a plausible association between PPI use and 
gastric carcinoids in humans16, however these case reports can be argued to be 
coincidental given the low prevalence of gastric carcinoids and the high prevalence of 
PPI use. More robust data comes from a RCT study in which 158 GERD patients 
undergoing laparoscopic anti-reflux surgery was compared to 180 patients treated 
with esomeprazole for 5 years. In this study it was found that despite a continued 
proliferative drive on enterochromaffin-like cells during esomeprazole treatment, no 
dysplastic or neoplastic lesions were found and no safety concerns were raised.17 PPIs 
have now been available for 25 years and post-marketing surveillance and prospective 
studies do not support a causal relationship between long-term PPI use and the risk of 
GI cancer. 
Nevertheless, in clinical practise the usage of PPI should be restricted to the approved 
indications and to patients who clearly benefit from treatment. Evaluation and follow-
up on treatment is important and includes discontinuing PPI, dose reduction of PPI to 
the lowest effective dose or step-down strategies. 
PPIs are mainly metabolized by the liver cytochrome P450 system. Slow metabolizers 
show greater acid-suppressive effect of PPI than rapid metabolizers. Omeprazole, 
lansoprazole and pantoprazole are mainly metabolized via the isoenzyme CYP2C19, 
while esomeprazole mainly involves CYP3A4.  PPI interacts with drugs that are 
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metabolized through CYP2C19 and/or CYP3A4, for instance ketoconazole, 
atazanavir and clopidogrel. PPIs also affect the absorption of drugs which are 
dependent on low pH (gefitinib and others).  
PPIs are recommended as gastroprotection in patients using clopidogrel and ASA. It is 
debatable whether PPI (especially omeprazole) blunts the CV protective effects of 
clopidogrel as has been shown in pharmacodynamic studies. However, high quality 
observational studies and one RCT study have not reported a significant increase in 
cardiovascular events for PPI users compared to non-PPI users.18 
1.6.3 Over-the-counter (OTC) use of acid-suppressive drugs 
Antacids and alginates are safe and readily available OTC medications with rapid 
onset. H2RA also provide rapid onset but with longer duration of response. PPIs are 
also available as OTC, but in smaller pack sizes and lower doses than PPI on 
prescriptions. OTC antacids and H2RA are suitable alternatives for self-treatment 
when symptoms are mild and infrequent.  
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2. Gastro-Esophageal Reflux Disease (GERD) 
2.1 Definition of GERD 
The Montreal consensus on the definition and classification of GERD states that 
GERD is a condition which develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications.19 GERD has different phenotypes and 
the disease is subclassified into esophageal and extraesophageal syndromes. The 
esophageal manifestations are divided into symptomatic syndromes and symptomatic 
syndromes with esophageal injury (figure 1). This aspect of the definition is an 
important change because it takes a more patient-centered approach in which GERD 
can also be diagnosed based on symptoms alone and in the absence of objective 
findings obtained with invasive examinations.  
 
Figure 3: Montreal definition and classification of GERD and its syndromes 
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2.2 Prevalence and incidence of GERD 
GERD is a wide-spread disorder with increasing incidence and prevalence. The 
prevalence is reported in the range of 10-20% in Western Europe and North America 
when defined as at least weekly heartburn and/or regurgitation.20 21 In Asia, the 
prevalence is lower, in the range of 2 to 5%, but likely increasing.  A Norwegian 
longitudinal cross-sectional study (HUNT) also reports a substantial increase in the 
prevalence of reflux symptoms, increasing from 12% in 1995-7 to 17% in 2006-9 
when defined as at least weekly symptoms.22 These estimates may represent an 
overestimation of the true prevalence of GERD given that symptoms at least twice 
weekly is the threshold definition which is thought to predict when symptoms 
significantly impair quality of life. King et al. tried to determine whether GERD 
patients can be grouped into distinct categories based on the impact of the disease.23 
They found three distinct groups; 'long-term, disrupting GERD' (39%) with symptoms 
considered to have not only high physical but also psychological impact. Patients with 
'recurrent, distressing GERD' (14%) experienced both physical and psychological 
impact and were worried about the recurrent, restrictive nature of their disease or the 
possibility of having a more serious underlying condition. Patients with 
'inconveniencing GERD' (48%) had less frequent symptoms with overall lower 
impact. In relation to the above figures the prevalence of individuals in the whole 
population of Norway, with at least one prescription dispensed on a PPI for acid-
related disorders, was 4.4% in 2006 increasing to 6.5% in 2011 (self-generated report 
from www.norpd.no). 
Incidence figures of GERD are much more difficult to estimate and one may have to 
follow individuals to see if they develop GERD. Symptoms also fluctuate with time 
making it difficult to define start of symptoms. The best estimates for the incidence of 
GERD, from U.K and U.S observational data, are 4.5 and 5.4 per 1000 person-years, 
respectively.24 25 The Norwegian longitudinal cross-sectional study reported an annual 
incidence of severe GERD of 0.23%.26  
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The natural course of GERD and proportion of patients with complete remission of 
symptoms or complication is equally hard to predict and is also different depending on 
the GERD phenotype. In a longitudinal cross-sectional population based study in 
Norway the annual spontaneous loss of reflux symptoms, not due to anti-reflux 
medications, was 1,22%.22  Six months after discontinuing omeprazole treatment, 
10% of patients with reflux esophagitis and 25% of patients with ENRD reported 
symptomatic remission. 27 This underlines that ENRD is a more heterogeneous group 
where sustained symptomatic remission is more difficult to accomplish compared to 
patients with reflux esophagitis.  Another RCT looked at the rate of maintained 
healing of reflux esophagitis and symptomatic remission on esomeprazole 40 mg q.d 
or placebo. After 6 months, 88% of patients on esomeprazole and 29% on placebo 
were maintained healed. Seventy-one percent and 15% respectively were still in 
symptomatic remission after 1month.28  
2.3 Pathophysiology and risk factors for GERD 
Why people develop GERD remains poorly understood. GERD is a multifactorial 
disease in which anatomical and functional factors both play a role. In simple terms 
one could say that GERD presents when there is sufficient contact of acid with the 
esophageal epithelium to produce symptom or tissue damage. The lower esophageal 
sphincter (LES) is a major component of the anti-reflux barrier and a dysfunction of 
LES is a likely cause of reflux events. The phenomenon of non-swallow related LES 
relaxations, called transient lower esophageal sphincter relaxations (TLESRs), was 
first described in 1980 and is now recognized as the predominant mechanism of 
reflux in patients with GERD.29 
The presence of a hiatus hernia (HH) is an important predisposing factor for GERD.30 
HH lowers the LES pressure, affects peristalsis and impairs esophageal clearance 
leading to an increased esophageal acid exposure. The prevalence of HH is higher in 
patients with reflux esophagitis (ranging from 50-80%) than in ENRD patients (10-
20%) in the Western world.31  In a random sample of 1000 subject in two northern 
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Swedish municipalities a hiatal hernia was found in 239 subjects (24%) and among 
those 116 subjects (49%) also had reflux esophagitis.32  HH is also a marker for 
GERD severity and correlates with reflux symptoms and the presence of BE. The 
presence of a HH increases with older age. At the present time the pathophysiological 
role of HH is not fully known and it is unclear whether HH aggravates acid reflux, if 
acid reflux contributes to the formation of HH or both. Meanwhile, HH is applied as a 
useful marker of more severe forms of GERD. 
The increasing prevalence of GERD coincides with the obesity epidemic and a good 
amount of evidence now exists for a causal relationship between obesity and GERD. 
A meta-analysis suggests that obesity is associated with a 1.5 to 2-fold increased risk 
of GERD symptoms and reflux esophagitis compared to individuals with normal Body 
Mass Index (BMI).33 Obesity is also a risk factor for developing severe complications 
of GERD, like Barretts esophagus (BE) and esophageal adenocarcinoma  (EAC).34 
From epidemiological data we know that the presence of GERD increases steadily 
with higher age until it peaks around 60 years of age and thereafter declines. In a UK 
primary care database study, the incidence of GERD increased with age in both men 
and women until the age of 69 years, from which point the trend was reversed.24 In 
the Georgia Medicaid study, a similar trend was observed, although the trend reversed 
earlier, at 55 years.25 In a large Norwegian cross-sectional population based study 
(HUNT) it was shown that in women, the prevalence of reflux symptoms increased 
gradually from 22.1% in the youngest age category to 37.5% in the oldest, while 
among men it gradually increased from 25.8% in the youngest age group to peak at 
36.0% between the ages of 50 and 60 years, after which it declined to 33.8% after the 
age of 70.21 
Observational studies have suggested that tobacco smoking may represent a risk 
factor for GERD.35 36 A case-control study on 3.153 patients with severe GERD-
related symptoms has shown that the duration of smoking was associated with 
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increasing reflux symptoms (OR, 1.7; 95% CI, 1.5-1.9) in subjects who had smoked 
for more than 20 years.37 
 
Gender, dietary habits and alcohol have all shown weak associations with unclear 
causality. Male gender is associated with more severe disease and a higher frequency 
of reflux esophagitis. 
2.4 Societal perspective and burden of illness 
2.4.1 Cost of illness 
GERD was the most common gastrointestinal diagnosis in the USA in 2009 followed 
by abdominal pain and gastroenteritis.38 According to Sandler et al., the total direct 
costs of GERD in the US in 2000 were USD 9.8 billion, resulting in costs of 
approximately USD 500 per patient and year.39 
A German longitudinal cohort study estimated the total costs of GERD per patient and 
year to €382. Sixty-four percent (64%) was cost of medication, 19% hospital-
generated costs, 7% physician generated costs and 10% indirect costs. Indirect cost 
relates to cost outside the healthcare system for instance transportation cost, loss of 
income and productivity loss due to GERD. A cost-of-illness study from the U.K 
estimated the costs for GERD to GBP 0.75 billion per year (2004).5 
The total cost to Swedish society of dyspepsia, peptic ulcer disease and GERD in 
1997 was $US424 million or $US63 per adult. Direct costs totaled $US258 million 
(61%) while indirect costs totaled $US166 million (39%). The highest proportions of 
costs were due to drugs and sick leave, 37% and 34%  respectively.40 
2.4.2 Upper GI endoscopies and pH-measurements 
The total number of upper endoscopies in the USA during 2009 was 6.9 million (23 
per 1000 inhabitants) generating a total cost of $12.3 billion.38 In 2003, £152 million 
was spent on 404.900 upper GI endoscopies in England (8 per 1.000 inhabitants).5  
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In Norway, the total number of EGDs performed in 2011 for GERD was 24.456 (5 
per 1000 inhabitants) representing 27% of the total number of EGDs (90.882).The 
number of EGDs undertaken at hospitals for GERD increased steadily from 9.600 in 
2002 to 19.000 in 2009 (a 100% increase). From 2009 the activity of EGDs seems to 
have stabilized at around 19.000 EGDs at hospitals and 5.000 EGDs at private 
institutions performed annually. The rise in utilization of total EGDs in the US during 
the same interval was 50.1%38 – a significantly lower increase compared to Norway 
(figure 4). 
The number of pH-metry examinations performed in Norway was 1.980 in 2009, 
2.308 in 2010 and 2.337 in 2011 (Source: report generated from Norwegian 
Directorate of Health, Norwegian Patient Registry).  
 
Figure 4: Number of EGDs performed for GERD in Norway during the period 2002 
to 2011. Activity data from private practitioners was available from 2008 (poor 
quality of data 2010).  Source: report generated from Norwegian Directorate of 
Health, Norwegian Patient Registry. 
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2.4.3 Primary care consultations for GERD 
Approximately 10% of all consultations in primary care are related to the digestive 
system. In a prospective observational study conducted in six European countries 
3.4% (in Norway 2.2%) of all consultations in primary care were for GERD related 
reasons.41 A postal survey of randomly selected samples of primary care physicians in 
six European countries showed there is a significant variation within Europe in the 
primary care management of GI diseases, which may be explained by differences in 
demography, disease perception, health care organization and primary/secondary care 
cooperation.42  
2.4.4 Health-related quality of life (HRQL) and indirect costs 
A number of studies have demonstrated that health-related quality of life (HRQL) in 
reflux disease patients is significantly impaired in comparison to the general 
population. Furthermore, this impairment is comparable to or greater than that 
observed for other chronic conditions, such as diabetes, arthritis or congestive heart 
failure.43 An increasing severity and frequency of GERD symptoms is associated with 
more concomitant diseases, lower HRQL, lower work productivity and increased 
healthcare utilization.44 45 Reflux symptoms that occur at least once per week are 
likely to have a negative impact on HRQL.46  
Sleep disturbances and dysphagia stands out as perhaps the most troublesome 
symptoms of GERD. There is a strong association between GERD and sleep 
disturbances such as shorter sleep duration, difficulty falling asleep, arousals during 
sleep, poor sleep quality, and awakening early in the morning.47 The reported 
prevalence of dysphagia or pain during swallowing was 37% in patients with reflux 
esophagitis.48  
Since GERD is a symptom-driven disease it also has significant impact on work 
productivity, both as absenteeism (due to sick-leave) and presenteeism (decreased 
productivity while at work). In an observational study at 134 primary care sites across 
 32 
six European countries the number of hours absent from work (absenteeism) due to 
GERD was in Norway estimated to 0.9 hours per week (SD=4.7). The GERD related 
work hours lost due to preseenteism, as assessed by the patient, was 6.7 hours/week 
(SD=6.2) as measured using the Work Productivity and Impairment Questionnaire 
(WPAI-GERD).49-51 However, the estimated value on presenteeism is unsecure due to 
recall bias and likely leads to an overestimation. Reflux symptoms also limit the 
patients’ participation in leisure and sport activities. 
2.5 Diagnosis of GERD 
The Montreal consensus on the definition and classification of GERD states that 
GERD is a condition which develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications.19 This statement underlines an 
important fact, namely that GERD can be diagnosed based on symptoms alone and 
without esophagogastroduodenoscopy (EGD) or pH-metry. The opposite situation, 
although less commonly encountered in clinical practise, with an asymptomatic 
patient presenting with complications also qualifies for GERD diagnosis. In support of 
this reasoning is one of the paradoxes in GERD, namely the imperfect correlation 
between symptoms of GERD and endoscopic findings. In the Kalixanda study a 
random sample of 1000 subjects from the general population in northern Sweden 
underwent EGD and was assessed on symptoms of GERD. The overall prevalence of 
reflux esophagitis was 15.5%. However, 36.8% of the subjects who were found to 
have reflux esophagitis reported no symptoms of GERD and 24.5% of patients 
reporting reflux symptoms had esophagitis.32  
Current guidelines on the diagnosis and treatment of GERD recommend that when 
the symptoms of GERD are typical (heartburn/regurgitation) and the patient present 
without any alarm features no invasive procedures like EGD and/or pH-metry are 
necessary to verify the working diagnosis.19 52-55 Alarm features include progressive 
dysphagia, weight loss, jaundice or haemorrhage, all which mandate prompt 
endoscopy. The risk of cancer and other co-morbidities increases with age and 
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therefore higher age (>50 years) most often is regarded a separate criterion for 
undertaking diagnostic EGD. In patients with long symptom history, typically > 5 
years, an early EGD is also indicated. Anxiety for underlying malignancy is another 
valid reason for performing EGD. According to current guidelines patients with 
confirmed BE should be followed regularly for development of dysplasia. 
2.5.1 Esophagogastroduodenoscopy (EGD) 
EGD is the best method by which esophageal injury can be detected. Endoscopic 
findings in GERD include reflux esophagitis, erosions and ulcers, strictures, hiatus 
hernia and Barrett’s esophagus (BE). The Los Angeles (LA) classification is 
frequently used for the grading of reflux esophagitis into four grades A-D and has 
facilitated research and treatment approaches.56 The diagnostic yield of EGD is 
modest because only about half of patients have visible reflux esophagitis in primary 
care when being referred to EGD.57 The prevalence of reflux esophagitis will 
however differ depending on the selected population, the level of the health care 
system and pre-endoscopy use of acid-suppressive therapy. 
Since the diagnostic value of EGD is limited the role of EGD is changing. For 
younger patients presenting without alarm symptoms upfront EGD is not the first 
measure. The indication for EGD referral to specialist includes persistent symptoms 
despite a trial of PPI treatment, atypical symptoms making the diagnosis less certain 
and alleviation of worries for underlying malignant disease. In a Norwegian interview 
based study on 280 patients with dyspepsia, ulcer and GERD patients were asked to 
evaluate their symptoms and main reasons for improvement one year after EGD. Only 
16% reported the reassurance by a negative endoscopy as important for improvement. 
It seems therefore that EGD is of limited importance for the subjective improvement 
in GERD.58  
The ideal timing of EGD is another central issue to consider. It is advisable that 
patients with persisting reflux symptom history should at some point in time have 
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EGD undertaken and preferably within 5 years of symptom début. One of the 
purposes of EGD is to identify Barrett’s metaplasia (BE) and pre-malignant lesions, 
and long symptom duration is a strong predictor for the development of BE and 
adenocarcinoma of the esophagus.59 Hence an early EGD might not be the best 
strategy since BE can be hidden within areas of the esophageal inflammation. If we 
accept that the main indication for EGD is to detect BE and cancer, EGD is best 
performed while the patient is on PPI therapy in order to better discern the metaplastic 
mucosa from inflammatory changes. Another suitable time for EGD is in conjunction 
with tapering off or discontinuing of acid-suppressive therapy. In most patients this 
will cause symptoms to re-appear. This will confirm the diagnosis and the chronicity 
of the disease and is a suitable time to refer to EGD and evaluate the need for long-
term medical or surgical therapy. If one accept the fact that the re-appearance of 
reflux symptoms defines the diagnosis of GERD it is also in this situation relevant to 
perform EGD while patient is on PPI therapy in order to detect complications not 
related to inflammation. 
 The American College of Physicians best practise advise states that EGD is indicated 
in patients with heartburn and alarm symptoms, in patients with typical GERD 
symptoms that persist despite optimal PPI therapy, to assess healing and rule out BE 
in patients with severe grade esophagitis, to detect EAC and BE in men >50 years 
with chronic GERD and additional risk factors and, lastly, for EGD surveillance every 
3 to 5 years in patients with history of BE.60  
The role of newer endoscopic techniques like magnification and high-resolution 
endoscopy and Narrow Band Imaging (NBI) will continue to be developed and likely 
find its place in clinical practice and improve the diagnostic yield of EGD.61  
2.5.2 Biopsies 
The advantage with EGD is that it can be combined with gastric or esophageal biopsy 
taking in order to detect microscopic changes of GERD, confirm the histopathological 
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diagnosis of BE and identify other differential diagnoses like eosinophilic esophagitis. 
In ENRD patients the utilization of biopsy taking seems an attractive approach to 
reach an objectively and histopathological confirmation of GERD. However, the 
diagnostic accuracy of esophageal biopsies has proved generally disappointing  and 
the general belief is that histology cannot be recommended for ENRD diagnosis.62 
2.5.3 Esophageal manometry 
Esophageal manometry is a method that measures pressure and coordination of 
pressure activity in the esophagus. It is indicated to evaluate suspected disorders 
related to impaired motility or peristalsis of the esophagus such as achalasia. In the 
diagnostic work-up for GERD it is used to locate the correct placement of the pH 
probe for pH-metry and is also indicated before anti-reflux surgery.  
2.5.4 pH-monitoring and impedance-pH-metry 
Ambulatory 24 hours pH-metry is performed with a pH-sensitive electrode placed 5 
cm above the LES and is regarded as the method with the highest sensitivity and 
specificity for GERD, but unfortunately it will not identify all patients with GERD. It 
is also resource demanding and costly and has limited availability in many health care 
systems. 
The association between symptoms and reflux episodes is an important piece of 
information determining the extent to which symptoms reported by the patient 
correlate with acid reflux. The symptom association probability (SAP) is the preferred 
method used today. With this method the 24 hours pH data is divided into 2-minutes 
segment and within each of these segments it is determined if acid reflux (pH<4) 
occurred and whether a symptom was reported. SAP values greater than 95% are 
positive regardless of percentage of time pH<4. 
The primary role of pH-metry is to diagnose GERD in patients with reflux symptoms 
but normal EGD, i.e. Endoscopy Negative Reflux Disease (ENRD).  
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A recent advancement in pH-monitoring is the incorporation of the electrode into a 
wireless capsule (BRAVO), which is attached to the esophageal mucosa, and 
transmits pH data to an external receiver over 48 hours or more. The advantage of the 
wireless system compared to conventional pH is improved patient tolerability and thus 
provide a more realistic and accurate picture of the acid exposure with enhanced 
sensitivity.  
Another method frequently applied is the combined pH-monitoring and impedance 
test. Combined impedance-pH testing has the advantage of assessing reflux events 
regardless of acidic content (i.e. measures also weakly acidic and alkaline content) 
and to assess their time correlation with symptoms. This method is increasingly used 
to examine patients on medication who do not respond to acid-suppressive therapy 
and as an assessment indicated before surgery. 
2.5.5 Symptom-based diagnosis 
Heartburn and regurgitation are the cardinal symptoms of GERD present in roughly 
70% of classical GERD patients. Heartburn is often characterized as the main 
symptom and is defined as a burning sensation in the retrosternal area (behind the 
chestbone). Regurgitation is defined as the perception of flow of refluxed gastric 
content into the mouth or hypopharynx.19 
Population-based studies have tried to define a threshold at which reflux symptoms 
become troublesome in the sense that they affect general well-being and daily living.45 
46 The Montreal classification of GERD discusses a threshold of mild symptoms on 2 
or more days a week or moderate/severe symptoms occurring more than 1 day a week 
as often being troublesome by patients. However, in clinical practice a more patient-
centered approach is recommended to determine whether symptoms are troublesome 
or not instead of an arbitrary cutoff for frequency and intensity of symptoms.19 
Current guidelines recommend a symptom-based approach for GERD in primary care 
for patients who are young, have a short disease history and no alarm symptoms.52-55 
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However, the symptom-based assessment is not straightforward either and often leads 
to misinterpretation of symptoms, including their localization and burden.63 The 
sensitivity and specificity of heartburn and/or regurgitation for GERD varies 
considerably depending on the criteria set for frequency and intensity of symptoms. 
GERD has also overlapping symptoms with differential diagnoses such as functional 
dyspepsia, irritable bowel syndrome, and extraesophageal syndromes like chronic 
cough, laryngitis and asthma. This is all adding to the complex symptomatology of 
patients with upper GI symptoms.19 64  
Against this background there have been several attempts to develop patient 
questionnaires (Patient Reported Outcome instruments) that can facilitate the 
symptom-based diagnosis and management of GERD. It is important that these 
instruments undergo proper evaluation including content and construct validity asking 
patients about the relevance of questions as well as linguistic validation. However, 
most of the patient questionnaires available are not developed or properly validated as 
diagnostic tools and, in fact, none of them satisfy the regulatory standards as recently 
issued by the Food and Drug Administration.65 The properties required of a 
questionnaire also depend on the setting in which it is intended to be used and if it 
supposed to be used and accepted in a regulatory setting. For the practical use of 
questionnaires in routine clinical care it is also equally important that questionnaires 
are not too long and complicated. In a review paper of the available patient 
questionnaires for GERD there were 5 instruments that met most of the regulatory 
requirements. The N-GSSIQ to assess nocturnal GERD symptoms,66 the PASS to 
identify persistent reflux symptoms while on PPI therapy,67 the ReQuest developed 
separately for in patients with and without esophagitis,68 the GSAS developed to 
measure treatment effects in clinical trials69 and the RDQ for diagnosis and evaluation 
of GERD in primary care and in clinical trials.70  
The ReQuest in Practise was developed as a shorter version of ReQuest and is 
intended for use in clinical practice.71 ReQuest in Practice comprises six dimensions 
‘acid complaints’, ‘upper abdominal ⁄ stomach complaints’, ‘lower abdominal ⁄ 
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digestive complaints’, ‘nausea’, ‘general well-being’ and ‘sleep disturbances’. For 
each dimension (except ‘general well-being’), distress is evaluated by means of a 100 
mm visual analogue scale (VAS) ranging from ‘not at all’ to ‘extremely severe’ 
(‘general well-being’: from ‘wonderful’to ‘extremely poor’). Dimensions related to GI 
complaints (‘acid complaints’, ‘upper abdominal ⁄ stomach complaints’, ‘lower 
abdominal ⁄ digestive complaints’ and ‘nausea’) form the subscale ReQuest in 
Practice-GI. The subscale ReQuest in Practice-WS covers the dimensions ‘general 
well-being’ and ‘sleep disturbances’. 
 
The GerdQ questionnaire is a simple, self-administered and patient-centered 
questionnaire including 6 items. The questionnaire was developed as an exploratory 
part of the Diamond study72 73 and the 6 items were derived from three questionnaires 
(Gastrointestinal Symptom Rating Scale – GSRS74, Reflux Disease Questionnaire – 
RDQ70 and the GERD Impact Scale – GIS75) used in the study. The GerdQ 
questionnaire asks patients to score the number of days with symptoms and use of 
over-the-counter (OTC) medications during the previous 7 days. It  uses a four graded 
Likert scale (0-3) to score the frequency of four positive predictors of GERD 
(heartburn, regurgitation, sleep disturbance due to reflux symptoms or use of over-the-
counter (OTC) medications for reflux symptoms) and a reversed Likert scale (3-0) for 
two negative predictors of GERD (epigastric pain and nausea) giving a total GerdQ 
score range of 0-18. The sleep disturbance and use of OTC medication are also used 
for assessment of the impact of GERD, giving a separate “impact score” ranging from 
0-6.  
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Question 
Frequency score (points) for symptom 
0 day 1 day 2-3 days 4-7 days 
1. How often did you have a burning feeling 
behind your breastbone (heartburn)? 
0 1 2 3 
2. How often did you have stomach contents 
(liquid or food) moving upwards to your 
throat or mouth (regurgitation)? 
0 1 2 3 
3. How often did you have pain in the centre 
of the upper stomach? 
3 2 1 0 
4. How often did you have nausea? 3 2 1 0 
5. How often did you have difficulty getting 
a good night’s sleep because of your 
heartburn and/or regurgitation? 
0 1 2 3 
6. How often did you take additional 
medication for your heartburn and/or 
regurgitation, other than what the 
physician told you to take) (such as Tums, 
Rolaids, Maalox?) 
0 1 2 3 
Table 1: The GerdQ questionnaire 
2.5.6 PPI test 
Empiric short-term treatment with PPI over 2-4 weeks has been widely used 
clinically, especially in primary care, as a way of indirectly diagnosing GERD through 
response to therapy. Given the fact that symptom relief is the treatment goal and that 
PPI are overall effective in most patients this is intuitively an attractive approach. 
However, responsiveness to treatment is not equal to diagnosis and patient may have 
other acid-related diagnoses. Previous studies have also documented that the PPI test 
has good sensitivity, but poor specificity for GERD.76-78 Thus the PPI test has limited 
value as a diagnostic strategy for GERD. 
2.6 Interventions for GERD 
GERD represents a disease with a wide spectre of endoscopic findings, symptoms and 
complications. Severity and the course of the disease also varies; from characteristic 
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reflux symptoms responding to therapy, refractory classic GERD not responding to 
therapy, atypical manifestations over to pre-malignant lesions (BE) and increased risk 
of esophageal adenocarcinoma (EAC). Treatment and follow-up of GERD therefore 
needs to be individualised. 
Occasional symptoms of heartburn and regurgitation are highly prevalent with as 
many as 40% in the general population reporting to have intermittent symptoms.79 In 
the vast majority of these individuals symptoms are light, triggered by food intake or 
physical activity. Many symptoms resolve spontaneously, do not affect general well-
being and therefore does not constitute reflux disease. Simple measures on life-style 
and diet as well as identifying triggers for symptoms will often be sufficient for 
symptoms to resolve. On the other hand there are also subjects with a high-symptom 
load being self-treated with high consumption of over-the-counter (OTC) acid-
suppressive medications that should be encouraged to seek proper medical care.  
2.7 Lifestyle modifications 
Many lifestyles advises are recommended for GERD including avoiding foods that are 
acidic or cause irritation (citrus fruits, tomatoes, onions, carbonated beverages and 
spicy foods) or foods that can cause gastric reflux by reducing the lower esophageal 
sphincter pressure (fatty or fried food, coffee, tea, chocolate). However, the clinical 
evidence of these measures is to a large extent incomplete.80 Behavioural lifestyle 
measures include smoking cessation, weight reduction, avoiding late and large meals 
and elevation of head of bed. 
2.8 Proton pump inhibitor treatment for GERD 
During the 1970s the H2RAs were introduced but they achieved only modest benefits 
in both clinical practice and controlled trials due to an insufficient effect on the pH of 
refluxed gastric juice. Omeprazole was introduced in 1988 and the PPIs have been 
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widely reported to afford more effective long-term symptom resolution, healing of 
reflux esophagitis and prevention of relapse than the H2RAs.52 81 82  
2.8.1 Comparative efficacy of PPIs in the treatment of GERD 
PPIs have been widely reported to afford more effective long-term symptom 
resolution, healing of reflux esophagitis and prevention of relapse than the H2RAs.52 
81 82 Furthermore, all the available PPIs provide high rates of symptom resolution of 
reflux symptoms with only small differences between different PPIs. In a meta-
analysis by Hunt et al. 77% of patients were symptom-free after 8 weeks with PPI 
compared to 48% with H2RA.81 In the same meta-analysis 85% of patients with reflux 
esophagitis were healed after 8 weeks on PPI compared to 52% on H2RA. In the 
healing of reflux esophagitis lansoprazole, pantoprazole and omeprazole in approved 
doses show similar healing rates.83 84 Esomeprazole 40 mg q.d was the first PPI to 
show a statistical advantage over the other available PPIs in healing rates of 
esophagitis and with the difference most enhances with the higher grade of 
esophagitis (LA grade C-D).85-87 After symptom resolution and/or healing of 
esophagitis has been achieved maintenance therapy is often needed long-term, or even 
life-long, since most patients relapse when stopping therapy. PPI seems more cost 
effective than H2RA in keeping patients in remission.88 89  
2.8.2 Rebound Acid Hypersecretion (RAH) 
Sustained hypergastrinemia due to daily PPI therapy causes increased acid-secretory 
capacity and RAH may appear when the drug is stopped. Reimer et al. conducted a 
randomized, double-blind, placebo-controlled trial in 120 healthy volunteers 
randomized to 12 weeks of placebo or 8 weeks of esomeprazole 40 mg/d followed by 
4 weeks of placebo. Forty-four percent of those randomized to PPI reported acid-
related symptoms in weeks 9–12, compared to only 15% in the placebo group 
(p<0.001).90 In a post-hoc analysis of several studies on patients with healed reflux 
esophagitis after 4 to 8 weeks with potent PPI therapy (dexlansoprazole 30, 60, 90 mg 
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or lansoprazole 30 mg) after which patients were re-randomized into maintenance 
treatment with dexlansoprazole or placebo. Among the 287 placebo treated patients 
there was no evidence of recurring heartburn symptom worsening beyond baseline 
levels within two months after stopping PPI therapy.91 In a smaller 62 patient trial no 
symptom rebound 12-14 days after 5 days on PPI could be proven, but treatment 
duration in this study is probably too short and RAH also assessed to early after 
stopping PPI.92 In 9 patients treated for 90 days with a PPI a significant increase in 
gastric acid output was seen 14 days after discontinuing PPI therapy, but symptom 
rebound was not assessed.93 In sum, the clinical relevance of rebound acid 
hypersecretion is not fully determined in GERD patients and further research is 
needed in patients who discontinue or tapering off their PPI therapy. Nevertheless, it 
is important to follow basic rules including regular follow-up of patients with periodic 
reconsideration of treatment needs, including discontinuation, tapering-off or 
stepping-down approaches to the lowest effective maintenance dose. Gradual 
cessation of PPI therapy may prevent acid-rebound.94  
2.8.3 PPI refractory GERD 
Patients with GERD who are not responding to proton pump inhibitors (PPIs) given 
once daily are very commonly seen in the clinic with as much as a third of patients 
with GERD being resistant or partial responders to treatment with PPI.  A higher rate 
of PPI unresponsiveness is seen in endoscopy negative reflux disease compared to 
reflux esophagitis.85 Commonly, doubling the PPI dose or switching to another PPI 
will be offered to patients who failed PPI once daily. Questioning on symptom 
patterns and triggers as well as securing adequate adherence to medication is 
important. Algorithms for the management of refractory GERD have been 
developed.95 Refractoriness to PPI suggests that there are other factors than acid that 
might play a role. Esophageal impedance with pH testing on therapy appears to 
provide the most relevant information about the subsequent management of these 
patients enabling the characterization of non-acid related reflux episodes.  
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2.8.4 Anti-reflux surgery 
Anti-reflux surgery is an alternative for some patients. Long-term studies comparing 
anti-reflux surgery with long-term PPI treatment has proven a similar outcome in 
improvement of symptom burden and quality of life.96 97 Potential candidates for anti-
reflux surgery should be young patients for whom potential life-long acid-suppressive 
therapy is unwanted. Patients should have typical GERD with a proven response on 
acid-suppressive therapy and with bothersome residual symptoms that cannot be 
completely resolved when optimizing medical therapy. Complications of GERD, 
primarily strictures, can also be indications for surgery. However, strictures are more 
rarely seen as a result of effective PPI therapy. The standard surgery method now is 
laparoscopic fundoplication which quickly has replaced the open method. 
Complications from anti-reflux surgery include dysphagia, bloating, post-prandial 
fullness and flatulence. A rather high proportion of operated patients will continue to 
take acid-suppressive drugs to control residual reflux symptoms. The rate of re-
operation is 2-10%. Anti-reflux surgery should be performed at specialist centres with 
adequate volume, experience and expertise to gain the best possible outcome. 
A magnetic sphincter device implanted by laparoscopic technique around the 
esophageal sphincter has shown to improve reflux symptoms and decrease PPI use in 
GERD patients with partial PPI response, however, larger follow-up trials of this new 
technique are warranted.98  
2.8.5 Natural course of GERD  
The issue on the natural course of GERD is debated. Some argue that they see 
progression of GERD over time,99 100 whereas others state the contrary with patients 
remaining in the initial stage with little movement between phenotypic expressions of 
endoscopy negative reflux disease (ENRD), reflux esophagitis (RE) and Barrett 
esophagus (BE).101 102 In a German prospective cohort study 2.721 GERD patients 
were characterized into ENRD without BE and RE without BE at baseline and 
 44 
followed for five years (EGD at 2 and 5 years). As an effect of treatment a small 
proportion with ENRD and mild/moderate RE progressed to severe forms of RE and 
regression from severe esophagitis to ENRD was frequently seen. Out of the 1.041 
ENRD patients at baseline, 10 patients (1%) at 2 years and 9 patients (1%) after 5 
years, had progressed to LA grade C/D. As an effect of active treatment there was also  
a regression of esophagitis among the 188 patients with LA grade C/D at baseline 
with 11% at 2 years and 9% at 5 years remaining in the same phenotypic grade.102  
There seems to be a correlation between baseline grade of esophagitis and the 
development of BE with 6% of the ENRD patients, 12% of the LA grade A/B patients 
and 20% of the LA grade C⁄D patients with no BE at baseline progressing to BE after 
5 years. The average rate of progression to BE was 10%.102  
The issue on progression of GERD is of great clinical importance since patients 
developing Barrett’s esophagus are also at increased risk of developing esophageal 
adenocarcinoma, with an estimated annual incidence of 0.5–1%. Since BE is a known 
risk factor for the development of esophageal adenocarcinoma (EAC) upper 
endoscopy surveillance is recommended each 2-4 years.  However, the results from 
two population based studies conducted in Ireland and Denmark found that the 
incidence of EAC was much lower than previously reported, 1.3 and 1.2 cases per 
1000 person-years.103 104 As the risk of BE patients to develop EAC has gradually 
been revised downwards the value of BE surveillance programs has been questioned.  
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3. NSAID induced upper gastrointestinal (UGI) 
complications 
3.1 Epidemiology of NSAID utilization 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely 
prescribed drugs in the world. 111 million prescriptions are written for NSAIDs in the 
USA annually.105  In Norway, 833.000 individuals had at least one dispensation of a 
physician prescribed NSAID in 2011, representing 17% of the total population (self-
generated report from www.norpd.no). In a population wide database study from 
Denmark 57.8% claimed at least one NSAID prescription during the period 1997-
2005.106 Usage of NSAIDs increases with age. In Norway, usage of NSAID in 2011 
peaked at the age interval 50-59 years in which 26% of the population had at least one 
dispensation of a physician prescribed NSAID followed by a decline in prevalence 
among individuals in ages above 80 years (self-generated report from www.norpd.no).  
NSAIDs are also available OTC in smaller pack sizes and lower doses and are very 
commonly used for self-treatment of pain and fever. A USA study found that among 
patients using prescribed NSAID, approximately 40% also used OTC NSAIDs at the 
same time.107 
NSAIDs are used to treat arthritis, musculoskeletal, menstrual and post-operative 
pain, as well as headache and fever. Most of the usage of NSAID is for short-term 
relief of pain and inflammation like light injuries, inflammation, fever and for 
intermittent pain. Consequently most NSAID prescriptions are for short-term use for 
one month or less.108 Many patients use NSAIDs intermittently or as required in 
response to the level of pain or discomfort. Long-term usage of NSAID is prevalent in 
chronic conditions like rheumatoid arthritis and osteoarthritis. A UK 
pharmacoepidemiological study found that unspecified musculoskeletal and soft tissue 
complaints were the dominant indications for prescribing NSAID while rheumatoid 
arthritis and osteoarthritis only accounted for 5% and 23% of all prescriptions.108 
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3.2 Mechanism of gastrointestinal injury from NSAIDs 
NSAIDs are believed to exert the gastrointestinal toxicity via two main mechanisms, 
namely, inhibition of prostaglandin (PG) synthesis and a direct topical injury. 
3.2.1 Inhibition of prostaglandin synthesis 
Both the therapeutic beneficial effects and adverse effects of NSAIDs are attributed to 
the inhibition of prostanoid biosynthesis (PGE2, PGD2, PGF2α, thromboxane A2 and 
prostacyclin I2). Prostanoids are generated intracellularly from arachidonic acid (AA). 
Free AA is converted to prostaglandin H2 by the activity of prostaglandin H 
synthases, also named cyclooxygenase-1 (COX-1) and cyclooxygenase (COX-2). 
Prostaglandin H2 is further metabolized into various other prostanoids by different 
synthases.109  
 
 
 
 
 
The two cyclooxygenase isoenzymes are differently regulated. COX-1 is expressed in 
almost all tissues and plays an essential homeostatic role in many physiological 
functions (GI protection, platelet aggregation and vascular smooth muscle 
modulation). COX-2 is an inducible isoenzyme and plays an important role in 
pathological processes such as inflammation, cancer and endothelial vasoprotection. 
Inhibition of COX-1 on platelets also reduces the production of thromboxane which 
leads to an aggravation of a present GI bleeding. Prostaglandins in the GI tract 
normally stimulate secretion of mucin and surface active phospholipids which protects 
the mucosa from gastric acid. Prostaglandins also stimulate secretion of bicarbonate at 
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the mucosal level. By inhibiting prostaglandin synthesis NSAIDs impair these 
defensive mechanisms and the mucosa becomes susceptible to damage by acid and 
pepsin leading to erosions and later sub-mucosal ulcers which can again develop into 
severe complications like bleeding and perforation.109 
3.2.2 Direct topical injury 
Most NSAID are weak organic acids which are unionised in contact with the gastric 
acid and diffuse freely into mucosal cells in which they become ionised due to 
elevated pH in the cells. Once in the cells, they became trapped giving rise to a high 
intracellular concentration which damages the cells directly.110 Today most NSAIDs 
on the market are enteric coated and do not get absorbed in the proximal GI tract. 
Consequently this is nowadays less of a problem. NSAIDs can initiate smaller 
erosions via a direct topical injury while prostaglandin inhibition causes 
ulcerations.111 
3.3 Classification of NSAIDs 
NSAIDs comprise traditional NSAIDs (tNSAIDs) and NSAIDs selective for COX-2 
(coxibs). COX1/COX2 selectivity is assessed in vitro using whole blood assays and 
defined by its relative potency to inhibit COX-1 and COX-2 activities by 50% 
(IC50).109 We can group NSAIDs into those being more selective for COX-1, such as 
naproxen and ibuprofen, and those more selective for COX-2 (most other NSAIDs). It 
has been shown in vitro that many tNSAIDs, for instance diclofenac, also has COX-2 
selectivity comparable to some coxibs.112 The degree of COX selectivity is also 
dependent on the dose administered. 
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3.4 Analgesic efficacy of different NSAIDs 
Comparative studies and meta-analyses have found that there are no clear differences 
between the different tNSAIDs in standard doses  with regard to treatment of 
osteoarthritis .113 Similarly more than 20 randomized clinical trials and systematic 
reviews have not found any meaningful efficacy difference between coxibs and the 
tNSAIDs.113 114 No significant differences have been found between the different 
coxibs in recommended doses.113 115 
3.5 Gastrointestinal complications of NSAIDs 
Symptoms and injuries of NSAID to the GI tract are very common and ranges from 
upper GI symptoms like reflux, dyspepsia and abdominal pain, to erosions and to more 
serious lesions such as ulcers which again can result in clinical manifestations such as 
bleeding, perforation or gastric outlet obstruction.  
3.5.1 Upper GI symptoms 
Upper GI symptoms (dyspepsia, epigastric pain and heartburn) is very common and 
occur weekly in about 10 to 40% of NSAID patients.116 117 Dyspeptic symptoms 
reduces quality of life and the patient may even refrain from taking their NSAID.116 
Dyspeptic symptoms are poorly correlated with endoscopic finding and clinical 
complications. In a study of arthritic patients, 91% of patients with abnormal 
endoscopy were asymptomatic whereas 19% of patients with dyspeptic symptoms had 
normal endoscopy.111 Another study showed that NSAID induced dyspeptic 
symptoms occurred in the absence of endoscopy detected gastroduodenal ulcers in 
approximately 50% of patients. A meta-analysis found that high dosages of any 
NSAID led to a 3-fold increased risk of dyspepsia compared to no use of NSAID 
while lower and recommended dosages did not significantly increase the risk of 
dyspepsia.116 
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3.5.2 Erosions and ulcers 
Erosions are superficial while ulcers penetrate the submucosal layer of the upper GI 
mucosa. A peptic ulcer is diagnosed at endoscopy when the diameter is 5 mm or 
larger and is covered with fibrin. A diameter less than 5 mm is defined as erosion. 
The typical location of a duodenal ulcer is the bulb (pars superior duodeni) where 
gastric content enters the small intestine. The predominant location of a gastric ulcer 
is the angular notch of the lesser curvature, however they can occur at any location 
between cardia and pylorus. NSAID caused ulcers most often manifests as gastric 
ulcers, while the predominant localization of H. pylori caused ulcers is the duodenum.   
Endoscopic ulcers commonly develop in NSAID users with a prevalence reported in 
the range from 15-30%.118 Most of these ulcers are asymptomatic and do not lead to 
complications.  
3.5.3 Upper gastrointestinal (UGI) complications and mortality  
Peptic ulcers can give raise to symptomatic ulcers and clinical manifestations such as 
bleeding, perforation and gastric outlet obstruction.  RCTs estimate the annual 
incidence of UGI bleeding and perforations to range from 1.0 to 1.5% in NSAID 
users.119-122 Observational studies and chemoprevention trials have indicated a three-
fold to five-fold higher risk of severe GI complications for patients taking NSAIDs 
compared with patients not taking NSAIDs.123 124  
In the USA (1997), hospitalisation and mortality due to NSAID related UGI 
complication have been estimated at 103.000 patients/year and 16.500 patients/year, 
respectively.125 In a review paper by Lau et. al. comprising a total of 93 studies the 
annual incidence of ulcer bleedings and perforations were 19-57 and 4-14 cases per 
100 000 inhabitants, respectively.126 In the same review paper by Lau including a total 
of 26 studies the reported mortality rate related to upper gastrointestinal bleedings was 
an average 8.6% (95% CI: 5.8-11.4).  In a Spanish cohort study the estimated 
proportion of UGI complications and deaths related to NSAID/ASA use was 36%. In 
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the same study the UGI mortality rate due to NSAID/ASA usage was estimated to 21-
25 deaths per million inhabitants per year.127 Transferred to Norway this should mean 
approximately 125 NSAID related deaths per year. In a UK modelling study based on 
a series of RCTs and observational studies it was estimated that 1 out of 1.200 
patients taking NSAIDs for more than 2 years will die from UGI complication who 
would not have died have they not taken NSAID.128  
The time trends show a declining trend in the incidence and prevalence of upper 
gastrointestinal bleeding. This is much explained by the availability to eradicate H. 
pylori and the falling prevalence of H. pylori infection. A Swedish registry study 
reports that hospitalization from bleeding ulcers decreased from 64 to 35 per 100 000 
inhabitants from 1987 to 2005.129 However, a Danish study reports a stable incidence 
of gastrointestinal bleeding from 55 cases per 100 000 in 1993 to 57 cases per 
100 000 in 2002.130 Increased use of NSAID and low-dose ASA have resulted in that 
drug induced ulcers representing a larger proportion of the total UGI complications.       
Previous reports have found that the highest risk for an NSAID related UGI 
complication is the first period after NSAID initiation. Compared to non NSAID users 
the risk was increased 8-fold in patients with NSAID treatment duration <1 months, 
3.3 fold in patients >1 but <3 months and 1.9 fold in patient having used an NSAID 
for more than 3 months.131 However, the estimate from RCT studies suggests that the 
rate of endoscopic ulcer events being relatively constant over time. 
3.5.4 Lower gastrointestinal complications 
NSAIDs may also cause damage to the lower GI tract beyond the duodenum. The 
lower GI complications of NSAID are, however, less well categorised and understood. 
Lower GI complications occur at a rate of approximately one-fifth the rate of upper GI 
complications.132 While UGI complication may show a falling incidence the incidence 
of lower GI complications tend to increase.133 In a systematic review of RCTs and 
observational studies  it was reported an increased event rate for lower GI 
complications of tNSAIDs compared to non-NSAID users and with coxibs carrying a 
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lower risk of lower GI complications compared to tNSAIDs.134 A case-control study 
from Taiwan reported an elevated risk of lower GI complications with both celecoxib 
(OR=2.3; 95%CI 1.0-5.6) and tNSAIDs (OR=2.3; 95%CI 1.8-2.9).135 PPI therapy 
would not be expected to protect against injury beyond the duodenum. The effect of 
misoprostol against lower GI complications has not been tested. 
3.5.5 Risk factors for upper GI complications 
Patients above the age of 65 years have a 2 to 4-fold increased risk of serious UGI 
complications with NSAID use compared to patients < 65 years.8  
Concomitant use of low-dose ASA for CV prophylaxis is very common among 
NSAID users (20-25%), but low-dose ASA also increases the GI risk. When NSAIDs 
are combined with low-dose ASA the risk of bleeding increases 2 to 4-fold as 
compared to low-dose ASA alone.136 Low-dose ASA also eliminates the GI benefits of 
coxibs compared to tNSAIDs. A nested case-control study found that the risk of UGI 
complication was higher among coxib plus low-dose ASA users (RR 1.9; 95% CI 1.0–
3.6) compared to coxibs alone (RR 0.6; 95% CI 0.4–0.9).137 
A prior ulcer or ulcer complication requiring hospitalisation is often recognised as the 
most important predictor for a future UGI complication and has been shown to give a 
2.5 to 4-fold increased risk of a new UGI clinical event.118 131  
With Warren and Marshall’s discovery of Helicobacter pylori the understanding and 
management of peptic ulcer disease shifted rapidly from being an acid related disease 
to a proven infectious disease.138 Epidemiological studies reveal a very strong 
association between H.pylori infection and the development of gastroduodenal ulcers 
and complications. In one study, the risk of ulcer bleeding was increased by a factor of 
1.8 with H.pylori infection, by 4.9 with NSAID treatment and by 6.1 in the presence 
of both.139 The H pylori infection can permanently be eradicated and cured by a short 
course of antibiotics in combination with PPI which effectively prevents relapse.  
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Anticoagulation by warfarin increases the risk of UGI complications in NSAID users 
by approximately 3-fold and treatment with corticosteroids double the risk.140 
There are also reports on a possible association between use of SSRIs and UGI 
complications. The biological theory behind this association is related to serotonin 
release from platelets that plays an important role in activating the aggregation 
process and SSRI leads to lower levels of serotonin inside the platelets. Previous 
observational studies have documented a low to moderately elevated risk with RRs 
estimates in the range from 1.2 to 3.7. However, in some of these studies the 
confidence intervals are wide and sometimes non-significant questioning the causality 
between SSRI exposure and UGI complications. One of the largest studies is a Danish 
case control study in 3.652 cases of upper gastrointestinal bleedings (UGB). 
Concurrent use of SSRI (n=377 cases) in this study was associated with an increased 
risk of UGB (OR=1.7: 95%CI 1.5-2.0) while concurrent use of both NSAID and SSRI 
(n=99 cases) increased the risk 8-fold (OR=8.0: 95%CI 4.8-13).141 
3.6 Comparative gastrointestinal toxicity of NSAIDs 
A nested case-control study showed a 3.7-fold (95% CI 3.1-4.3) elevated risk with 
tNSAIDs and a 2.6-fold (95% CI 1.9-3.6) elevated risk with coxibs of developing 
serious upper GI complication compared to non-users of NSAID.137 A review of RCT 
and meta-analyses estimated that coxibs was associated with a 61% relative risk 
reduction for ulcer complication compared to tNSAIDs.142 Another systematic review 
found that the relative risk of upper GI bleedings and perforations was greater with 
tNSAIDs (RR 4.5; 95% CI 3.8-5.3) than with coxibs (RR 1.9; 95% CI 1.0-3.7) 
compared to non-NSAID users, although the risk varied between the individual 
NSAIDs.143 Consequently, even if a coxib reduces the risk of UGI complications, this 
risk is not reduced to baseline. 
The comparative GI toxicity of different tNSAIDs is a subject of discussion. In a 
meta-analysis of 11 observational studies comparing the risk of bleeding and 
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perforation ibuprofen had the lowest relative risk (RR=1.0) with diclofenac (RR=1.8) 
and naproxen (RR=2.2) doubling the risk.144  
There is also a relationship between NSAID dose and the risk of UGI complications. 
In the meta-analysis by Henry et al patients with high dose ibuprofen had the same 
risk as patients using naproxen or indomethacin.144 In a UK based case-control study 
patients using NSAIDs in high doses had a higher risk of UGI complications than for 
low doses (RR=7.0 95%CI; 5.2-9.6 vs. RR=2.6 95%CI;1.8-3.8), with non-NSAID 
users as reference.124 
3.7 Cardiovascular toxicity of NSAIDs 
An increased incidence of thrombotic events of coxibs was first shown in RCTs 
investigating celecoxib, rofecoxib and valdecoxib for colorectal adenoma 
chemoprevention.145 146 This finding led to the withdrawal of valdecoxib and 
rofecoxib, but also sparked the research activities within this field. This has led to the 
knowledge that all NSAIDs are associated with varying degree of cardiovascular 
risk.147 In the meta-analysis by Kearney et al. coxibs were associated with a 
moderately increased risk of vascular events, largely attributable to a twofold 
increased risk of myocardial infarction. There were no differences in risk between the 
different coxibs. In the same study no significant difference was found in the 
incidence of serious vascular events between participants treated with a coxib 
compared to those treated with a tNSAID, but there was a marked heterogeneity 
between the different tNSAID, particularly with a lower incidence of CV 
complications seen with naproxen compared to non-naproxen NSAIDs.147 The 
mechanism of the increased CV hazard with NSAIDs is suggested to be associated 
with the profound inhibition of PGI2 which is atheroprotective and generated by 
COX-2.148 The increased CV risk caused by PGI2 inhibition could be balanced by a 
concomitant inhibition of COX-1 and generation of the pro-aggregatory mediator 
TXA2. However, most tNSAID and coxibs do not completely inhibit platelet COX-1 
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with therapeutic doses. Naproxen is different in this respect as it shares a potent 
COX-1 inhibition with a long half-life and this has been proposed as the mechanism 
by which naproxen could have a more beneficial CV profile compared to the other 
tNSAIDs.  
3.8 Prevention of UGI complications 
As alluded previously the mechanisms for the development of gastrointestinal damage 
caused by NSAID therapy is attributed to the inhibition of the prostaglandin 
biosynthesis and direct topical injury. When mucosal defence is weakened it becomes 
more exposed to damage by acid and pepsin. Consequently acid and pepsin is only a 
co-factor, albeit an important one, for the development of peptic ulcer disease and 
gastroprotection with PPI elevates pH and inactivates the damage of pepsin if pH is 
over 4. 
The main goal for gastroprotection is to reduce the clinically significant GI 
complications of NSAIDs, since erosions, and even ulcers, most often are 
asymptomatic and do not lead to complications. Nevertheless, in RCT studies, 
endoscopically detected ulcers have been a recognised surrogate for UGI 
complications like bleeding and perforation.149 Regulatory agencies, like the FDA, 
also endorse the use of the incidence of endoscopic ulcers as a surrogate efficacy 
endpoint for gastroprotective therapies. This partly explains why neither PPIs nor 
H2RAs have been assessed in large prospective randomized trials using the more 
clinically relevant endpoints such as bleeding and perforation as the primary outcome 
measure. Consequently, the evidence of the value of gastroprotective therapy in 
preventing UGI complications comes largely from observational studies. 
The primary preventive measure to reduce GI complications in patients where NSAID 
therapy cannot be stopped is to restrict all NSAID use to the lowest possible dose and 
to minimize the duration of therapy. H. pylori should also be eradicated in patients 
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with a previous ulcer history. Concomitant drugs like corticosteroids, anticoagulants 
low-dose ASA and anti-platelet agents should be avoided, if possible.  
3.8.1 Gastroprotective drugs for NSAID induced GI damage 
For patients with an elevated risk of UGI complications, concomitant gastroprotective 
therapy with a PPI, misoprostol and/or a choice of a coxib is recommended.8 150 From 
a cost-effectiveness perspective only patients with one or more additional risk factors 
should receive gastroprotective therapy.  
RCTs with PPIs have documented a 60-80% decreased relative risk of developing 
endoscopically verified gastroduodenal ulcers compared to placebo.151-153 PPIs are 
well tolerated in most patients, however, the risk of clinically important interaction 
(clopidogrel) and side-effects induced by long-term acid-suppression should be 
considered (see chapter 1). PPIs are superior to H2RA in standard doses for the 
prevention of both gastric (RR=0.32; 95% CI 0.17-0.62) and duodenal ulcers 
(RR=0.11; 95% CI 0.01-0.89).154  
Misoprostol, a synthetic prostaglandin analogue, have been shown in several studies 
to reduce the incidence of endoscopically diagnosed ulcers.120 However, misoprostol 
needs to be administered three to four times daily and has poor tolerability with one-
third of patients experiencing side-effects, primarily GI complaints such as abdominal 
pain and diarrhoea.120 Misoprostol appears superior to standard doses of H2RA on 
this indication. PPIs have never documented superior efficacy as gastroprotective 
therapy compared to misoprostol. However, due to the side-effects and the high 
frequency of administration of misoprotol, the use of misoprostol is today limited. 
Double dose of H2RA is associated with a statistically significant reduction in the risk 
of both duodenal and gastric ulcers compared to placebo, while standard dose only is 
effective at reducing the risk of duodenal ulcers, not gastric ulcers.152 However, 
because tachyphylaxis will occur with chronic use of H2RA, a standard dose of a PPI 
is the therapeutic strategy most often preferred over H2RA. 
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For patients with very high UGI risk and with a recent UGI complication a 
combination of coxib and PPI has been shown to offer greater GI safety than a coxib 
alone.155 156 In the 1-year study by Chan et al recurrent bleeding occurred in 9% with 
celecoxib alone compared to no recurrent bleedings with celecoxib plus 
esomeprazole.155 The regulatory labelling of coxibs in Europe states they are 
contraindicated in patients with current and history of CV disease.  
3.8.2 Treatment guidelines and algorithms 
The choice of gastroprotective strategy for patients in need of NSAID therapy needs 
be tailored and balanced to both the GI and CV risk in the individual patient. Current 
guidelines therefore recommend individual risk stratification to be applied in clinical 
practise.8 157 158 159  
Table 2 provides an overview of the suggested strategies balancing the GI and CV 
toxicity when prescribing NSAIDs. 
                 GI risk category 
 
CV risk category 
No or low GI risk with 
NSAID use 
GI risk with NSAID use 
No CV risk (without low-
dose ASA) 
tNSAID Coxib or tNSAID+PPI. 
Coxib+PPI for those with 
a history of GI bleeding 
CV risk (with low-dose 
ASA) 
Naproxen. Addition of a PPI 
if low-dose ASA+NSAID 
combination  
PPI irrespective of 
NSAID. Naproxen if CV 
risk outweighs GI risk.  
Table 2: Recommendations of the use of NSAID treatment based on GI and CV risk (table 
adapted from Scheiman et al.160 and Patrignani et al.109) 
However, the compliance with current guidelines and regulatory requirements is 
documented to be a challenge in many health care systems. Despite current guidelines 
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recommending gastroprotective therapies, as many as 60-80% of patients with an 
increased GI risk (≥1 risk factor) do not receive prescribed gastroprotective therapy.8  
A cross-sectional study in 17.000 patients showed that in >50% of patients the 
prescription of NSAID was not in accordance with recommendations.10 In a large 
Irish teaching hospital clinicians were asked to estimate UGI risk and comment on 
PPI gastroprotection in hypothetical patients. Half of the patients with multiple risk 
factors on admission and almost a third of patients at discharge were not prescribed 
gastroprotection.9 The Norwegian Institute of Public Health has in their annual drug 
consumption report for Norway estimated that, in 2011, among individuals above 65 
years using chronic NSAID treatment (≥100 DDD in 2011), 24% concomitantly 
received a PPI.11 However, this was all PPI use also including therapy for other upper 
GI diagnoses. 
3.8.3 Methods by which adherence can be measured 
Direct methods of measuring adherence are by observing intake of medication or by 
measuring the concentration of drug/metabolite in blood. While these measures are 
frequently used in ordinary clinical practice it is rarely feasible to adapt these direct 
methods in research due to practical constraints and high costs.  
Indirect measures of adherence are more frequently used. Counting the remaining 
tablets is frequently applied in RCT studies, but again this is an indirect measure of 
drug intake. A simple standardized posed question or a patient self-reported 
questionnaire can also be used, but introduces the problem of recall bias. Electronic 
systems attached to the tablet container or drug dispensing unit have been developed 
and introduced in research. This method gives an accurate time point of opening the 
container/unit, but again we cannot measure direct intake. Treatment response can be 
used as a surrogate measure of drug intake, but provides an inaccurate and not 
preferred method of assessing adherence. 
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A more attractive approach which has gained interest and frequently applied in 
pharmacoepidemiological research is to utilize large prescription databases in 
assessing drug adherence. The proportion (or percentage) of days of supply during the 
time between refill intervals is a frequently used method (This method has several 
names including medical possession ratio “MPR”, proportion days covered “PDC” 
and continuous medication availability “CMA”).  Another prescription database 
method called the maximum gap method defines a threshold of a maximum time gap 
between refills during an observation period.161 
3.8.4 Adherence to gastroprotective treatments 
The WHO definition of adherence is the following: “The extent to which a person’s 
behaviour – taking medication, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from a health care provider”.162 Adequate 
adherence to medications is vital for effective management of many chronic diseases 
and poor adherence is associated with increased morbidity, frequent hospital 
admissions, deterioration of quality of life and productivity loss. However, there is 
limited data on the costs of poor adherence to health care budgets. One US based 
study concluded that the costs for the health care system for inappropriate drug 
handling in general equal the costs for the whole drug bill in the US.163 An arbitrary 
cutoff level of ≥80% of medications taken according to the instructions is often used 
in research to describe an adherent patient.161 
In a Dutch cohort study on 784 adults who were new NSAID users and who were 
concurrently prescribed a PPI or a H2RA, 37% of patients were non-adherent.164 In 
the same study adherence seemed to decrease with a longer duration of therapy and 
number of reiteration of PPI prescriptions with the lowest rate of non-adherence with 
the first prescription refill (9%) increasing to 61% in patients with ≥3 prescriptions 
refills. 
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In the nested case-control study by van Soest et al incident NSAID users above the 
age of 50 years and using gastroprotective medications, conducted in England, the 
Netherlands and Italy, showed that 68% were adherent to concomitant 
gastroprotective therapy. Poor adherence was associated with a doubling in the risk of 
UGI complications (OR=2.4; 95% CI 1.7-3.4) compared to patients with full 
adherence.165 
A US based managed care database study estimated that 68% of NSAID treated 
patients receiving concomitant gastroprotective therapy had good adherence (≥80%). 
In the same study patients with poor adherence (<80%) had an approximately two-
fold increased risk of UGI complications compared to fully adherent patients 
(OR=2.4; 95% CI 1.0-5.6).166 
In a smaller case-control study, patients with poor adherence (<20%) had a four-fold 
increased risk of UGI complications compared to fully adherent patients (≥80%) 
(OR=4.0; 95% CI 1.2-13.0) while patients with intermediate adherence (≥20% to 
<80%) had an approximately two-fold increased risk (OR=2.5; 95%CI 1.0-6.7). The 
risk of an UGI complication increased with 16% for every 10% decrease in adherence 
of gastroprotective therapy.167 
In sum, the risk of an UGI complication in NSAID treated patients seems to increase 
2- to 4-fold in patients with poor adherence to concomitant gastroprotective therapy. 
Apart from the case-control study by van Soest165, which comprised 339 cases of UGI 
events among NSAID and concurrent PPI users gathered from three European 
countries, all the previous studies are too small and/or performed on a selected patient 
material questioning the causal association between PPI adherence and UGI events. 
The case-control study performed as a part of this thesis represents the largest study of 
its kind evaluating the association between adherence to concomitant PPI therapy in 
NSAID users and the risk of upper GI complications. We were able to identify 917 
UGI cases using NSAID with concomitant PPI therapy. The nationwide and complete 
health registers in Sweden provided us with a unique source of data encompassing the 
 60 
entire population of NSAID users in Sweden with regard to co-prescription of PPIs 
and to estimate the true risks of adverse events with varying adherence to PPIs over a 
period of 4.5 years. The high number of patients and events furthermore allowed us to 
adjust for known risk factors, and analyze in depth the different sources of bias so 
important to allow for a proper interpretation of studies with this design.  
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4. Aims of the studies 
4.1 Paper 1 – GerdQ validation study 
The aim of this study was to assess the diagnostic validity of GerdQ in a population 
with suspected GERD referred for open-access EGD.  
4.2 Paper 2 – GerdQ management study 
The aim of this study was to evaluate effectiveness and costs in use of the GerdQ in a 
symptom-based management algorithm to diagnose and select initial medical therapy 
compared to an invasive approach with EGD before initiating therapy, in patients with 
symptoms of GERD, but with no alarm features. 
4.3 Paper 3 - PPI drug utilisation study 
To assess the natural drug utilization patterns for PPIs. Firstly during a period 
unaffected by policy changes and, secondly, PPI utilization when a mandatory change 
in reimbursement policy for PPIs in GERD patients was introduced. 
4.4 Paper 4 - PPI adherence in NSAID users  
The aim of this study was to examine the association between PPI adherence in 
current NSAID users and the risk of UGI complications 
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5. Material and Methods 
5.1 Paper I/II – GerdQ validation and management study 
5.1.1 Design, approval and ethics 
This was an open, randomized, parallel-group multi-centre study conducted over 4-8 
weeks and performed at 18 gastroenterology outpatient clinics in Norway. Before any 
study procedures were conducted, the study protocol was approved by the 
Independent Committee for Research Ethics in Western Norway. Eligible patients 
were referred for symptoms suggestive of GERD and randomized in equal numbers to 
follow either (1) the new structured pathway (NSP) with diagnosis and treatment 
based on the GerdQ score or (2) the ordinary clinical pathway (OCP) comprising 
endoscopy, and if necessary and available, pH-metry (figure 5).  
This design also gave us the unique possibility to utilize the data from patients 
randomized to the OCP arm, and to perform a diagnostic validation study of the 
GerdQ.   
 
 
Figure 5: Design flow-chart of the GerdQ management study 
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5.1.2 Selection criteria and type of patients 
Eligible patients had symptoms suggestive of GERD (heartburn or regurgitation as 
predominant symptoms), were aged t18 years and provided written informed consent. 
Patients presenting with alarm symptoms such as unintentional weight loss, severe or 
progressive dysphagia, or GI bleeding were excluded as well as patients who had 
undergone endoscopy and/or pH-metry during the last year. Pre-endoscopy use of 
acid-suppressive medications was restricted in accordance with existing local 
guidelines, usually forbidding continuous use of both PPI and H2RA two weeks 
before EGD, but allowing limited on-demand use of antacids or H2RA.  
5.1.3 Management pathways 
New structured pathway (NSP) 
For the symptom-based approach a pre-defined algorithm was constructed. Based on 
the GerdQ score at baseline patients were subdivided into 3 different groups each 
with a pre-defined algorithm deciding on acid-suppressive treatment; 
– Low likelihood of GERD (GerdQ total score 0-7) treated at the discretion of the 
investigator 
– High likelihood of GERD and low symptom impact (GerdQ total score 8-18 and 
GerdQ impact score 0-3) starting treatment with a generic PPI in standard doses 
– High likelihood GERD and high symptom impact (GerdQ total score 8-18 and 
GerdQ impact score 4-6) starting treatment with esomeprazole 40 mg once daily.  
Ordinary clinical pathway (OCP) 
The investigator initiated treatment according to ordinary clinical practice and in line 
with current rules for reimbursement in Norway, which specifies generic PPI in most 
patients and esomeprazole only for severe esophagitis, complications such as 
strictures and metaplasia or symptoms refractory to treatment. 
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5.1.4 Analysis and statistical methods 
GerdQ validation study 
In the diagnostic validation study Receiver Operating Characteristic (ROC) curves 
with associated 95% confidence intervals (CI) were used for estimating the optimal 
cutoff value for a GERD diagnosis and its associated sensitivity and specificity (SE 
and SP). 
GerdQ management study 
The main statistical hypothesis in the management study was non-inferiority of NSP 
to OCP. We assumed 85% response rate in both groups and the non-inferiority (NI) 
margin was set to 10%.  
5.2 Paper III - PPI utilization study 
5.2.1 Design, approval and ethics 
This was an observational study using nation-wide and complete data from the 
Norwegian Prescription Database (NorPD) which contain all drug dispensation from 
pharmacies in Norway. Data was provided fully anonymized from the registry holder 
and hence approval from an Independent Ethics Committee was not required.  
5.2.2 Selectioncriteria and type of patients 
We studied all dispensations on a PPI between 1 July 2004 and 31 December 2008 
and being covered by the National Insurance scheme was retrieved. Three different 
cohorts of patients were studied; (i) Utilization in new PPI users in a period before the 
policy change; (ii) Utilization in new PPI users in period after policy change and (iii) 
Patients using esomeprazole at the time of the policy change. 
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5.2.3 Analysis and statistical methods 
Descriptive statistics was used to describe proportions of patients with any given 
feature.  
5.3 Paper IV - PPI adherence in NSAID users  
5.3.1 Design, approval and ethics 
In this case-control study data on all hospital admissions between 1997 and 2009 were 
retrieved from the Swedish National Patient Registry (NPR).168 Data on all dispensing 
of prescription drugs to outpatients were retrieved from the Swedish Prescribed Drug 
Registry.169  
The registry holder, the National Board of Health and Welfare, was responsible for 
linking data on individuals between these two registries and the research group was 
provided a fully anonymous dataset with each individual identified by a unique ID 
number. The research project was approved by the Regional Ethical Review Board at 
the Karolinska Institutet, Stockholm. 
5.3.2 Selection criteria and type of patients 
The initial study material included all individuals with at least one prescription of 
NSAIDs (excluding glucosamine) from the prescription registry, from its start on 1 
July 2005 until 31 December 2009. From the prescription registry, all other relevant 
co-medications were retrieved. From the NPR, we collected information about all 
outpatient and inpatient hospital admissions from 1 January 1997 until 31 December 
2009 and outpatient visits at hospitals from 1 January 2002 until 31 December 2009. 
A case was defined as the first ever UGI complication recorded in the NPR from 1 
January 1997 until 31 December 2009. As all patients were incident and current users 
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of NSAID, the cases with UGI complications were retrieved during the interval from 
1 July 2006 to 31 December 2009. Cases were identified using the relevant ICD-10 
codes for peptic ulcer (K25-K28) or GI bleeding (K92). 
Five controls to each eligible case were randomly sampled among all event-free, 
current, and incident NSAID users at the calendar time of the event. The controls 
were matched to the same age and sex, and had the same duration of NSAID 
treatment. 
A PPI-exposed NSAID treatment episode was defined as an episode where the 
individual either had a supply of PPI at the start of the NSAID treatment episode 
and/or had at least one dispensing of PPI during the NSAID treatment episode. 
The degree of PPI coverage (adherence) was estimated as the available supply of PPI, 
assessed as number of DDDs divided by the duration of the NSAID episode. 
5.3.3 Analysis and statistical methods 
The matched case–control study was analyzed using conditional logistic regression, 
and results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). 
The final adjusted model included co-variates with confounding properties on the 
basis of change of estimates. Effect modification was assessed using a continuous 
adherence variable. Sensitivity analyses were done excluding other gastroprotective 
medications and GI cancer, IBD, coagulation dysfunction and chronic liver disease 
co-morbidites. 
 67 
6. Summary results 
6.1 Paper I – GerdQ validation study 
A GerdQ cutoff ≥9 gave the best balance with regard to sensitivity, 66% (95% CI 58-
74%), and specificity, 64% (95% CI 41-83%), for GERD. We conclude that GerdQ is 
a useful complementary tool used for the diagnosis of GERD. Symptom resolution on 
PPI did not predict GERD. 
6.2 Paper II – GerdQ management study 
A symptom-based management approach for GERD using GerdQ reduced health care 
costs without loss in efficacy. Patients with high symptom scores on GerdQ profited 
from empirical treatment while patients with low symptom scores on GerdQ benefited 
from invasive investigations. An algorithm based on GerdQ may provide physicians 
with a tool for a more structured care of patients. The implementation of GerdQ could 
reduce the need for upper endoscopy and improve resource utilization. 
6.3 Paper III – PPI utilization study 
Despite GERD being a chronic disease there was a considerable alteration in the 
utilization of PPIs. Firstly, a high proportion had no refill indicating mild symptoms or 
long-term remission. Secondly, a high proportion was new users of PPI. The 
switching between different PPI was low indicating good efficacy and tolerance. The 
policy change was more effective in new patients compared to the mandated shift in 
ongoing esomeprazole users. 
6.4 Paper IV – PPI adherence in NSAID users 
A total of 3.649 cases were identified. Patients with poor adherence (< 20% PPI 
coverage) had a significantly increased risk of upper gastrointestinal complications 
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(OR = 1.88; 95% CI 1.22–2.88) compared with fully adherent patients (≥80% PPI 
coverage). As a continuous variable, the risk of an event increased with 6% points for 
every 10% decrease in PPI adherence (OR= 1.06; 95% CI 1.03–1.10). 
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7. General discussion 
What is common in the management of both GERD and UGI complications caused by 
NSAID therapy is that gastric acid contributes to the pathogenesis, and that acid-
suppressive medication is effective in order to resolve symptoms, heal mucosal injury 
and prevent complications and recurrence.  
The two acid-related diseases studied in this thesis represent two common reasons 
why patients contact health care. Due to sometimes severe symptoms and 
complications the patients affected can have a deterioration of quality of life with 
frequent health care consultations. The resource utilization for health care providers 
and society is substantial. 
Consequently, new and effective management strategies for GERD and for NSAID 
gastroprotection have the potential to improve cost-effectiveness without 
compromising on outcome. 
7.1 GERD 
7.1.1 The GerdQ questionnaire for diagnosis and management 
In order to facilitate the symptom-based diagnosis and follow-up of patients several 
attempts have been made to developed patient-centered questionnaires. The choice of 
the relevant questionnaire is dependent on if it is intended to be used in research, for 
regulatory purposes or to be integrated as part of ordinary clinical practise.  For use of 
a questionnaire in clinical practice there is a need to balance the information needs 
with the required simplicity a questionnaire has to have in order to be successfully 
implemented in routine care. A consequence of this balance between simplicity and 
information is that the GerdQ does not assess the important symptoms of dysphagia or 
extra-esophageal symptoms (atypical symptoms) of GERD. Although we were aware 
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of these short-comings of the GerdQ we still consider the GerdQ to be the best 
available and simple questionnaire to be integrated in routine primary care practise. 
We have with this research, firstly, provided results from a true validation study of the 
GerdQ questionnaire used as a diagnostic tool in patients with suspected GERD. It 
was concluded that the GerdQ is a simple and easy to use questionnaire that will 
complement and facilitate the management of patients with upper GI symptoms. 
Secondly, we integrated the GerdQ questionnaire into a management study where it 
was shown that for the diagnosis and initial treatment of GERD, patients randomized 
to a symptom based and questionnaire assisted approach, had the same efficacy 
outcome, but to a lower cost, compared to patients randomized to the ordinary and 
invasive approach using EGD and a subsequent pH-metry in ENRD patients.  
7.1.2 Clinical implications and recommendations 
Based on the results provided in this thesis it is argued that the pragmatic use of the 
GerdQ in primary care is as a sorting tool to help identify patients in need of further 
diagnostic work-up with EGD and pH-metry and referral to specialist care. Based on 
this a management algorithm for the diagnosis and treatment of GERD has been 
suggested (figure 6).  
For patients with classical GERD symptoms and higher GerdQ scores the working 
diagnosis based on symptoms should suffice and PPI treatment started without 
investigation. Upfront EGD, and possibly a subsequent pH-metry, will be indicated in 
patients above the age of 50 years, those presenting with alarm symptoms, anxiety for 
underlying malignancy and with long symptom history.  
If the primary care physician is to be responsible for the symptom based diagnosis and 
initial treatment of patients with typical GERD it must be accompanied with a regular 
follow-up of patients in which medication are adjusted or discontinued. Specialist 
referral to EGD is relevant for patients having persistent reflux symptoms despite 
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adequate treatment (PPI refractory) and for all patients within 5 years after initial 
symptom based diagnosis.  
 
 
Figure 6: Proposed management algorithm for GERD with the integrated use of the 
GerdQ questionnaire. 
The optimal timing of EGD in a symptom-based algorithm for GERD is an important 
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alarm symptoms, anxiety for underlying disease or long symptom history at 
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2. Unsatisfactory response after 4-12 weeks of optimised PPI therapy. In patients 
with PPI refractory disease EGD is best performed after 2 weeks off PPI-therapy 
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patients in primary care there is a risk of over-utilization of PPI which in turn can lead 
to increased costs of medication and unnecessary side-effects. Likewise, without a 
proper primary care follow-up of GERD patients, the opposite situation with under-
utilization of PPI can lead to deterioration of patient’s quality of life and loss of 
productivity. 
7.1.3 Modelling of the symptom-based approach 
So the important question to ask is if a change in the management of GERD patients, 
going from an invasive to a symptom-based approach would result in a cost-saving? A 
modelling of this scenario is difficult and has to be based on a number of assumptions 
with some obvious and inherent uncertainties. It was not the purpose of this thesis to 
perform a complete cost-of-illness evaluation of the different management 
approaches. Anyway, in the following chapter the consequences are discussed. 
Number of yearly EGDs 
We know that approximately 25 000 EGDs are performed for GERD each year in 
Norway. With an average direct medical cost of 3.359 NOK/EGD (as estimated in 
paper II) the annual costs of all EGDs performed for GERD in Norway would be 
approximately 84 million NOK. All indirect costs are not taken into account in this 
estimate and since many GERD patients are still working productive, this would lead 
to an underestimation of the total societal costs of EGDs. It is assumed from paper II 
that up to 60% of the initial EGD could be saved. However, since for most patients 
GERD is a life-long condition a majority of patients will eventually return for EGD at 
a later time point. It is also unclear whether the incidence and prevalence of GERD 
will continue to increase. Nevertheless, with all the sources of errors, it is anticipated 
that the number of EGDs could be reduced to 18 000, a net reduction with >7 000 
EGD per year. 
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Number of newly diagnosed GERD patients per year 
The estimated number of new GERD patients in Norway is approximately 20 000 
patients per year. This estimation is based on the publically available incidence 
estimates of 5 new cases of GERD/1000 person-years (U.K and US data)24 25 giving, 
when extrapolated to the population of Norway, a total of 25 000 new GERD patients 
per year. The Norwegian  HUNT study estimated the annual incidence of reflux 
symptoms (GERS) from 3.1% (any) to 0.23% (severe)22 and when extrapolating this 
estimate to the population of Norway it ranges from 153 000 to 11 499 new patients 
per year. However, the estimate from HUNT originates from a cross-sectional study 
using a symptom assessment only made on the basis of one simple question on the 
frequency of reflux symptoms. Clearly most of these persons do not have the 
diagnosis of GERD and the true estimate is probably in the lower end of this interval. 
Referring back to the number of EGDs undertaken annually for GERD in Norway 
being 25 000, and taken into account that a proportion of these EGDs are for follow-
up purposes,  20 000 new patients seems a sound estimate.  
Proportion of patients with sustained remission of GERD 
In a symptom-based approach with empirical PPI therapy one has to take into account 
the proportion of patients achieving sustained symptomatic remission not requiring 
further contact with health care. This category of patients will initially respond 
effectively to PPI therapy and after discontinuing PPI treatment the residual symptoms 
will be mild and/or infrequent. These residual symptoms can be self-treated, either by 
avoiding triggers, change in life-style and/or the use of OTC medication. The 
proportion of patients gaining lasting symptomatic remission is a matter of debate. In 
RCT studies, in which patients were re-randomized to either PPI therapy or placebo as 
maintenance therapy, after an initial phase with PPI in which either symptom 
resolution or healing of esophagitis was obtained, the proportion of patients with 
lasting remission was 10-25% over a 6 month period.27 28 91 Interestingly, from the PPI 
utilization study (paper III), the proportion of patients not having PPI refilled during a 
subsequent 12-month period was 23%. GERD is a chronic-relapsing disease and 6 to 
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12 months is probably a too short time-span in order to fully estimate the true 
proportion of patients obtaining a sustained symptomatic remission. For the purpose 
of this modelling we estimate the proportion of GERD patients with sustained 
remission not requiring prescription of acid-suppressive therapy to be 15%. 
Importance of time span 
The time perspective is also relevant to consider. From paper I it was hypothesized a 
saving of up to 60% of the primary EGDs in new patients with typical GERD and 
high GerdQ scores. A change to a symptom-based approach will firstly result in 
sustained remission, or cure, of GERD in approximately 15% of new patients. For the 
remaining patients, having typical GERD and high initial GerdQ scores, EGD will be 
indicated after an initial 1-3 months of PPI therapy in recommended doses without 
symptom resolution (PPI refractory), after 5 years history of GERD, or if alarm 
symptoms appears. 
Primary and secondary care collaboration 
An extra demand will be put on primary care physicians if the responsibility of the 
diagnosis is to be done more often in primary care. It has been estimated that 2.2% of 
all consultations in primary care in Norway is due to GERD. It is likely that this will 
increase to a European average, which was 3.4% in the same study.41 In 2010, the 
average number of consultations was 2.5 per inhabitant giving a total number of 
consultations in primary care amounting to 12 222 365 (source: Statistics Norway). 
This will give 268 892 (2.2%) consultations for GERD in primary care. It is estimated 
that the consultations will increase to 415 560 (3.4%), representing a net increase of 
146 668 consultations.  
From the data collected from the Norwegian Patient Registry (NPR) we know that the 
total number of specialist consultations for GERD (as both main and secondary 
diagnosis) was 46 312 in 2011.  Out of those, 24 478 (53%) involved EGD and 2 337 
(5%) involved pH-metry. It is estimated a total of 32 000 consultations for GERD in 
specialist care, a net reduction with 14 000. 
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Utilization of acid-suppressive medications 
As discussed in chapter 1.6 and figure 1 the prevalence of PPI consumption increases 
with a yearly rate of 10%. Furthermore 6.5% of the Norwegian population had at least 
one PPI prescription dispensed during 2011 (reimbursed and non-reimbursed). There 
is obviously a risk of an even higher increase in the PPI consumption if the 
reimbursement policy rule for PPI therapy is altered by letting the primary care 
physicians prescribe PPI for first time users without the requirement of specialist 
referral. In that respect EGD has served as an effective gatekeeper for a restrictive PPI 
use in Norway. It is also known that the consumption of PPI is higher in other 
countries, particularly in Southern Europe.  
A comparison with Sweden will give a sound estimate of the potential increase in PPI 
consumption. Sweden has for long adopted a primary care approach for GERD 
patients.  A self-generated report from the Swedish Drug Database shows that the 
consumption of PPI in 2009 was 44 DDD per 1000 inhabitants per day or 8.4% of the 
Swedes had at least one PPI prescription filled during 2011. During the same years in 
Norway the consumption was 36 DDD per 1000 inhabitants per day or 6.5% with at 
least one prescription filled. Consequently the PPI consumption is roughly 20% higher 
in Sweden than in Norway. 
From a cost perspective it has been shown in chapter 1.6 that the total costs for PPI 
therapy has fallen despite the yearly 10% increase in prevalence. All the PPIs, with 
the exception of esomeprazole, are available as non-branded cheaper generic 
alternatives. Soon, when esomeprazole also becomes generic, the costs for PPI 
treatment will be reduced even more. Esomeprazole represented in 2011 60% of the 
total drug PPI drug costs (NOK) and 40% of the total utilization (in number of 
DDDs). It needs to be remembered that the yearly cost for PPI treatment, with the 
anticipation of 1 DDD taken daily, is not more than roughly 1200 NOK or 3 NOK per 
day. When omeprazole 20 mg was introduced in 1988 the cost was 32 NOK per tablet 
(in 1988 value). 
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PPI use on unclear indications and unsatisfactory follow-up routines including failure 
of tapering down or discontinuing PPI therapy has contributed to an over-utilization 
of PPI therapy.6 7 13 It is important that primary care takes the responsibility for 
adequate follow-up in order to avoid over-utilization. 
Productivity loss and societal costs 
A symptom-based approach have the obvious advantage that patients in need of 
effective acid-suppressive therapy can have that prescribed by their primary care 
physician without having to wait for referral and EGD. Today, if not alarm symptoms 
are present, the waiting time for EGD is long and during waiting time productivity 
loss and sick leaves due to GERD is likely to lead to a considerable cost for society 
and unnecessary patient suffering.  
Table 3 gives rough estimates on the anticipated and potential consequences of the 
two management approaches for GERD. 
 Current 
situation 
Symptom 
based 
approach 
Number of yearly EGDs 25 000 18 000 
Primary care consultations for GERD per year 269 000 416 000 
Yearly specialist consultations for GERD (not EGDs) 21 000 14 000 
Number of patients with PPI (one dispensation yearly) 322 000 386 400 
Table 3: Modelling the health care consequences of the two different management 
approaches. 
7.1.4 PPI utilization and mandatory prescription policy changes 
There is scarce data on the real-world utilization of PPIs in patients with GERD. This 
thesis provides new intriguing data on the natural usage pattern for PPIs in the 
treatment of GERD. In a nation-wide registry study we have shown that despite 
GERD being a symptom-driven and chronic disease there is a significant alteration in 
the PPI usage patterns. Thirty-nine percent of esomeprazole users, during a period of 
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policy change, and 23% of PPI users, during a period without policy change, had no 
refill of PPI during the subsequent 12-months indicating mild symptoms or long-term 
symptomatic remission. The switch between different PPI was low when not 
influenced by policy changes. In contrast, a mandatory policy change, lead to a 
relatively moderate switch from esomeprazole to a generic PPI.  
A symptom-driven disease like GERD is highly sensitive to changes in treatment. 
Mandatory and not always clinically justified changes in reimbursement are difficult 
to accomplish in ongoing PPI patients with a considerable resistance to treatment 
changes by both doctors and patient. In Norway, PPI treatment must be initiated by a 
specialist and it may be more difficult later on for a primary care physician to change 
therapy that was once started by a specialist. For the 36% who still performed a switch 
25% had to switch back to esomeprazole again. Altogether, this strategy might not be 
cost-effective when taking the whole health care costs is into account as is also 
supported by North-American data.170 171 On the contrary, mandatory policy changes 
in treatment are effective for restricting the use of new esomeprazole users as it was 
reduced from 56% (before) to 20% 9-12 months after the implementation of the 
policy.  
Interestingly, the introduction of the therapeutic substitution programme for PPIs in 
Norway also resulted in a needed revision of the treatment needs in a large proportion 
of patients as was seen with the elevated proportion of patients (39%) permanently 
discontinuing esomeprazole treatment. 
7.1.5 Strengths and limitations of the studies on GERD 
The absence of a gold standard for the diagnosis of GERD complicates the clinical 
diagnosis as well as the development and validation of new diagnostic questionnaires 
for the diagnosis of GERD. The best available current method uses a combination of 
findings on EGD and pH-metry. In comparison with diagnostic methods applied in 
other areas of medicine, EGD and pH-metry lack the sensitivity to be regarded as a 
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gold standard for the diagnosis. While the absence of a perfect test hampers both the 
development and interpretation of new diagnostic methods for GERD, EGD and pH-
metry are currently the best methods we have at hand.  The results need to be 
interpreted in the light of this dilemma. The addition of esophageal biopsy taking 
identifying microscopic esophagitis in ENRD patients and/or upgrading of the pH-
metry to the BRAVO technique might have improved diagnostic precision further. 
However, since as many as 81% of patients had reflux esophagitis on EGD it is not 
likely that this would have resulted in a substantial improvement of the diagnostic 
accuracy. In paper I we have also shown that the diagnostic accuracy of the GerdQ 
was not further improved by the addition of a positive outcome on a PPI test.  
Limitations of the GerdQ management paper (Paper II) is that we are only evaluating 
the first 2 months of management and ideally the duration of the study should have 
been extended to 6-12 months, or even longer in order to capture the consequences 
long-term. Retrospectively, a post-study EGD/pH assessment of patients randomized 
to symptom-based approach (NSP) would have added important information. 
Additionally we were not able to collect pH-metry data from 14 ENRD patients. 
We have not studied a pure primary care population, but decided to use 
gastroenterologists as investigators and endoscopy waiting list as the primary source 
for recruitment of patients. One has to bear in mind that selection of patients occurs 
both at the primary care physician level, deciding on which patients to be referred to 
specialist for EGD, and from the investigator (gastroenterologist) deciding on which 
patients are eligible for the study. In sum, this resulted in a selection of patients 
towards being more GERD specific. A pure primary care population contacting 
primary care for troublesome upper GI symptoms would have given a more realistic 
primary care picture, with more functional and atypical complaints, and also as a 
result a lower prevalence of reflux esophagitis. 
The GerdQ management study was designed as a non-inferiority trial hypothesizing 
that the two pathways were equally efficacious in relieving symptoms of reflux. The 
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non-inferiority margin was set to 10%, i.e. NSP could not be more than 10% worse 
than OCP in order to conclude that this pathway was non-inferior. The 10% non-
inferiority margin was based on clinical judgement and pragmatic limitations. A lower 
non-inferiority margin would have resulted in a requirement to recruit a considerably 
higher number of patients. Retrospectively, it is reassuring that the symptomatic 
approach (NSP) had a trend for better efficacy over OCP when analysed for 
superiority. 
The strength of the diagnostic validation and the management study (paper I/II) is that 
we have applied a RCT design minimizing selection bias and providing good quality 
data. We have tried to limit the selection criteria in order to as much as possible 
mimic ordinary clinical practice. The participating investigators were all board 
certified endoscopists. 
The strength of the prescription database study is the opportunity we had to gather a 
nation-wide and complete patient material encompassing all PPI users in Norway 
from a public health care system. The advantage of prescription databases is that the 
absence of PPI dispensations, during a defined time period, can be used as a proxy for 
disease remission. The limitation of all prescription database studies is that we study 
pharmacy dispensations of drugs instead of the actual intake by the patients.  
7.2 PPI gastroprotection in NSAID users 
The results from this case-control study confirms that poor adherence (<20%) of 
concomitant PPI therapy in current NSAID users results in a doubling of the risk of  
peptic ulcer or bleeding compared to full adherence (≥80%). The risk was reduced 
with 6% for every 10% decline in PPI adherence. 
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7.2.1 Clinical implications and recommendations 
The problem with gastroprotective co-therapy is two-fold. Firstly, there is a significant 
under-prescription of gastroprotective therapy in at risk patients, which has been 
estimated to only 20-40%. Secondly, when gastroprotection is co-prescribed there is a 
challenge to maintain adequate adherence to gastroprotective therapy over time. 
The first measures, before gastroprotection is considered, is to reduce the risk of UGI 
complications in NSAID users by discontinuing, reducing the dose and/or shortening 
the duration of NSAID therapy. Other first measures include overseeing and 
potentially changing the use of other drugs known to cause or potentiate the risk of 
UGI complications (low-dose ASA, warfarin, corticosteroids and anti-platelets). Since 
most UGI events occur shortly (< 1month) after NSAID initiation adequate 
gastroprotection must be started simultaneously with NSAID (again restricted to the 
defined risk groups). Upper GI symptoms correlate poorly with endoscopic signs and 
UGI complications and since most NSAID related UGI events are silent, symptoms 
cannot be used as a signal to start gastroprotective therapy.  
Concrete measures to increase adherence include intensifying follow-up especially in 
fragile subgroups like the elderly using poly-pharmacy. Another method is to use dose 
dispensing which means that the patient’s medicine is packed in disposable bags 
corresponding to the dose that he or she needs to take during the course of one day. 
This is an attractive approach for elderly outpatients using poly-pharmacy and may 
contribute to a more rational use of drugs in general and improve adherence. 
However, there are few studies performed on the effectiveness of dose-dispensing on 
rational drug use and costs.172 
Another alternative to improve adherence to gastroprotective therapy is to use a fixed 
combination tablet containing an NSAID and gastroprotection in the same tablet. This 
gives the apparent advantage of obtaining full gastroprotection in every single dose of 
NSAID administered. The diclofenac+misoprostol (Arthrotec®) combination has been 
available for prescription for some time, but the use is limited due to misoprostol 
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related side-effects (abdominal pain and diarrhoea) and frequency of administration. 
Recently, a fixed combination of naproxen (500 mg b.i.d) with esomeprazole (20 mg 
b.i.d) (Vimovo®) have been introduced on the market. Vimovo has, in patients with 
osteoarthritis of the knee, been shown to possess comparable gastrointestinal 
protection as with celecoxib, both used in standard doses.173-175 Other fixed 
combinations available in countries outside Norway are ketoprofen (in three doses 
100, 150 and 200 mg q.d.) in combination with omeprazole (20 mg q.d) marketed as 
Axorid® and Keithon®.176 The regulatory approval of this combination is based on 
bioequivalence studies only and no RCT studies using incidence of endoscopic ulcers 
as the clinical endpoint have been performed. A fixed combination of ibuprofen (800 
mg daily) and famotidine (26.6 mg daily) (Duexis®) is also available in some markets. 
RCT studies with this combination has been shown to significantly reduce the risk of 
endoscopic ulcers compared to ibuprofen alone.177 
7.2.2 Strengths and limitations 
Previous observational data have demonstrated an association between poor PPI 
adherence and the risk of UGI complication. However, most of these studies are to 
small resulting in imprecise estimates of uncertain causality or they have been based 
on selected materials collected from primary care databases. Our study collected a 
nation-wide and complete dataset from registries in Sweden and thereby eliminated 
selection and re-call bias. The large dataset also made it possible for us to adjust for 
risk factors and analyse in depth the different sources of bias so important for studies 
of this kind. 
Observational studies are also best suited for evaluating the influence on PPI 
adherence and the risk of UGI complications, as randomized clinical trials usually 
control adherence and do not reflect real-world clinical practice. 
Both NSAID and PPI exposure was assessed by dispensed prescriptions. Thus, 
adherence was measured through the patient’s supply of PPI rather than what was 
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actually consumed. Another limitation is that the prescription registry does not 
contain information on the indication of use for the dispensed drug. Consequently, we 
were not able to assess the effect of adherence among patients using PPIs for 
gastroprotection alone and those having PPIs for other indications. 
We did not have information on over-the-counter (OTC) use of either NSAID or PPI, 
but defining the study cohort on the basis of dispensed prescriptions of both NSAID 
and PPI makes it less likely that OTC use of these drugs would be of importance. We 
did not have access to patient records and discharge summaries for verification of 
diagnoses. A further limitation lies in the comorbidities assessed in the study as the 
patient registry only contains information on hospital-based patient contacts, and 
consequently, typical diagnoses handled in primary care are underrepresented. 
In retrospect a further improvement of this study would have been to perform a 
separate and nested case-control study on all patients having any PPI coverage of the 
NSAID episode preceding the event. This would have given pure estimates within the 
different categories of PPI adherence in relation to each other. Instead we decided to 
present the results in a step-wise approach by, firstly, giving the risk estimates for PPI 
versus non-PPI users and, secondly, the risk estimates for adherence only for patients 
with any PPI coverage.  
A bias was introduced in estimating the effect of PPI adherence in individuals with 
short NSAID duration since it automatically leads to a large proportion of patients 
with full PPI adherence (91% in paper IV). Therefore a restricted analysis only on 
individuals with at least one reiteration of PPI (≥ 2 PPI refills) would have been 
interesting to perform. This would lead to more naturalistic, and possibly higher, 
estimates of risk related to poor adherence. However, it would also likely lead to loss 
of power giving more imprecise, and perhaps not-statistically significant, estimates.  
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8. Conclusion and future perspectives 
8.1 GERD 
In the validation study, the GerdQ questionnaire was confirmed to have a sensitivity 
and specificity likely to make it a useful and complementary tool for the diagnosis of 
GERD. In the management trial the symptom-based approach, facilitated by GerdQ, 
was proven to be an efficacious and cost-effective approach for the initial 
management of patients with GERD.  
Based on the results provided in this thesis it is argued that the pragmatic use of the 
GerdQ in primary care is as a sorting tool to help identify patients in need of further 
diagnostic work-up and referral to specialist care. A management algorithm for the 
diagnosis and treatment of GERD has been suggested (figure 6).  
From a patient perspective a symptom-based approach has the obvious advantage of 
giving patients early access to effective treatments at the primary care level. A pre-
treatment EGD requirement also leads to sub-optimal treatment and deterioration of 
quality of life and productivity loss during the EGD waiting time. Since symptoms 
correlate poorly with endoscopic findings patients with normal EGD are more 
exposed to not receiving a proper medical care. It has also been shown that, from the 
patient perspective, a normal EGD is of minor importance for outcome.58 
In a public health care system with limited budgets there is a constant strive for 
optimal usage of the limited resources available. The sharp increase in EGD 
examinations for GERD during the last decade might indicate an overuse of EGD in 
Norway. From a gastroenterological hospital perspective, resources which are now 
spent on sometimes unnecessary diagnostic EGDs, should instead be directed to an 
increased colonoscopy activity in patients at risk of colorectal cancer.  
It is clearly a difficult task to fully elucidate the total societal and health care 
consequences and costs implicated on the two different strategies (invasive or 
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symptom-based). From the previous discussion in section 7.1.3 it is anticipated an 
increased demand on primary care and a modest increase in PPI consumption. Costs 
for PPI treatment will likely continue to fall. It is also difficult to predict the future 
trend of the PPI consumption, but perhaps have we reached a plateau. Increased focus 
on over-utilization and fear of long-term side-effects will likely affect consumption. It 
is difficult to predict the future of the GERD epidemic, but given the increased focus 
and trend in the society on health, also helped by public health initiatives focused on 
obesity, tobacco and alcohol consumption, many factors can contribute to a fall in the 
incidence of this, at least partly, life-style modifiable disease.  
From a Norwegian health policy perspective this research provides both clinical and 
economic arguments for lifting the restrictions on the mandatory EGD required in 
order to prescribe reimbursed acid-suppressive therapy for the first time. In order to 
realize the full potential with a new structured care it will require the implementation 
of a national guideline for the management of GERD being developed by the medical 
community and sanctioned by the health authorities. This guideline should contain 
important aspects of care such as a description of the proper collaboration between 
primary and secondary care, describe the questionnaire assisted symptom based 
diagnosis and detail the indication for referral to specialist.  
Since patients with GERD first present in primary care, and the majority of patients 
should be taken care of in primary care, more research is needed in a primary care 
setting. Hence, a natural continuation of this research is to conduct a similar 
management study in a true primary care setting. A cluster randomized design 
splitting primary care centres into two groups following either an algorithm facilitated 
by GerdQ or following the ordinary management of patients with upper GI symptoms.  
Even though GERD in most patients is a chronic-relapsing condition the proportion of 
patients discontinuing PPI treatment was astonishingly high. There was only a limited 
switch between different PPIs probably as a result of therapy failure and/or side-
effects. A mandatory and policy-driven change in PPI prescriptions was difficult to 
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accomplish, led to a large degree of patients reverting to their original PPI and even 
enhanced the proportion of patients discontinuing PPI treatment. Health authorities 
should carefully assess the potential cost-saving for mandatory switch program which 
includes not-clinically motivated changes in ongoing patients. As shown, this is 
difficult to accomplish in symptom-driven diseases like GERD, and will likely lead to 
increased activity and costs in other parts of the health care system. A reduced drug 
cost, but a higher net health care cost has been documented from other PPI mandatory 
switch programmes in North America.170 171 
A relevant continuation of this research would be to utilize and link several health 
registers in Norway as a method to study the natural course of GERD (the prescription 
database, the cause of death registry, the hospital patient registry, cancer registry and 
socioeconomic and demographic individual level information data). Incident PPI 
users (identified as first PPI dispensation) on diagnostic code for GERD could be 
used as a proxy for a new diagnosis of GERD and provide the index date. From the 
index date and onwards all relevant information on demography, co-medication, co-
morbidities and mortality is gathered from the available population and health 
registers. 
A more properly conducted cost-of-illness assessment on the consequences of PPI 
policy changes can be conducted by gathering the cost of drugs from the prescription 
registry. Information from other health registries, like the patient registry for hospital 
visits, could help to assess the implication of drug policy changes on other part of the 
health care system. 
8.2 PPI gastroprotection in NSAID users 
The main finding was that NSAID treated patients with poor adherence to 
concomitant PPI therapy had a doubling of the risk of peptic ulcer or bleeding 
compared to patients with full PPI adherence. This confirms the results from similar 
studies documenting the importance of maintaining a satisfactory adherence to 
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concomitant gastroprotective PPI therapy over time. With our study, being the largest 
observational study on this topic, we were able to present, yet lower, but more realistic 
estimates on the association between PPI adherence and the risk of UGI 
complications.  
It is likely that the future will bring increased use of dose-dispensed drugs and 
combination tablets (NSAID+PPI) as important measures in individuals with 
anticipated poor adherence and established risk factors. The limited evidence on the 
value of dose-dispensed drugs in reducing UGI complication rate warrants additional 
research. The many different combination products which are likely to enter the 
market should be evaluated from a real-world clinical, tolerability and health-
economic perspective. 
The management of gastroprotective therapy in NSAID is complex and needs to 
balance risk of CV and GI complications. Therefore the development of pragmatic 
management algorithms that can be implemented in clinical practice is a preferred 
strategy going forward. This upfront risk stratification seems important, since the 
majority of UGI complication occurs early and less than 1 month after NSAID start. 
The adherence to these management algorithms should preferably be monitored 
gaining empirical evidence of the value of them. 
Another future challenge is the increased incidence of lower GI complications caused 
by NSAID therapy. Additional research is needed in this field in order to better 
categorize the different sub-groups of lower GI complications. Since PPI therapy have 
no effect beyond the duodenum other, not acid-suppressive, treatment strategies needs 
to be developed. It has been shown in observational studies that coxibs might be an 
effective gastroprotective strategy in the lower GI tract, but this needs to be further 
tested in prospective trials. The role of misoprostol as a gastroprotective strategy in 
the lower GI tract has not been tested in clinical trials. 
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The future of personalized medicine will probably bring the development of genetic 
and biochemical markers that can identify potential responders/non-responders and, 
likewise, individuals being more susceptible to develop either GI or CV side-effects of 
NSAID therapy. 
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